{"meta":{"query_hash":"583d3ed4173f","filters":{"venue":"JTO Clinical and Research Reports"},"cohort_total":76,"direct_labels_cover":0,"predictions_cover":76,"exported":76,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/583d3ed4173f","api":"https://metacan.xera.ac/api/v1/cohort?venue=JTO+Clinical+and+Research+Reports"},"results":[{"id":"W3043913046","doi":"10.1016/j.jtocrr.2020.100078","title":"Development and Validation of Diffuse Idiopathic Pulmonary Neuroendocrine Hyperplasia Diagnostic Criteria","year":2020,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Actelion Pharmaceuticals; AstraZeneca","keywords":"Medicine; Pathological; Univariate analysis; Univariate; Cohort; Multivariate analysis; Radiology; Hyperplasia; Lung; Multivariate statistics; Internal medicine; Pathology","score_opus":0.13887727792884494,"score_gpt":0.44360860754363957,"score_spread":0.30473132961479465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043913046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906904,0.0010314379,0.0000052364135,0.008575007,0.0000966973,0.00068717176,0.000002605631,0.000043992142,0.00048881257],"genre_scores_gemma":[0.99630314,0.002281864,0.0006223756,0.00023679333,0.00024430218,0.000051335646,0.0000103640905,0.000027588134,0.00022225808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599814,0.00042435317,0.001124122,0.0006983488,0.0012724791,0.0004825772],"domain_scores_gemma":[0.9967886,0.0013884467,0.00015289802,0.00032306614,0.0004371033,0.00090989313],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0015327766,0.00016199244,0.0005610773,0.00014051005,0.00013243614,0.00004186307,0.00008667028,0.000019121106,0.000043940192],"category_scores_gemma":[0.029518643,0.00012188425,0.00006917709,0.00033189685,0.0006886858,0.00013821345,0.0004938983,0.00082899834,0.00000945945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012328465,0.0012462216,0.764584,0.0019597213,0.000070981354,0.16018541,0.00016638883,7.3902885e-7,0.023862422,0.000056650457,0.001470312,0.045164328],"study_design_scores_gemma":[0.0036605953,0.0051495233,0.7302581,0.00093908724,0.0000936686,0.03868434,0.0004236331,0.00045849427,0.09659592,0.0011270903,0.12213626,0.0004732925],"about_ca_topic_score_codex":0.000017479877,"about_ca_topic_score_gemma":0.0000024223261,"teacher_disagreement_score":0.12150107,"about_ca_system_score_codex":0.000015331952,"about_ca_system_score_gemma":0.0003157246,"threshold_uncertainty_score":0.9786561},"labels":[],"label_agreement":null},{"id":"W3049475230","doi":"10.1016/j.jtocrr.2020.100083","title":"Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC","year":2020,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation; Eisai; Boehringer Ingelheim; Roche","keywords":"Medicine; Radiation therapy; Cohort; Curative treatment; Stage (stratigraphy); Retrospective cohort study; Surgery; Population; Chemotherapy; Palliative care; Radiosurgery; Internal medicine; Disease","score_opus":0.2690976024827529,"score_gpt":0.5162934747583426,"score_spread":0.24719587227558976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049475230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9360215,0.0039660726,0.00011508937,0.05780302,0.00021741116,0.0011300497,0.000011698495,0.000019456476,0.00071570923],"genre_scores_gemma":[0.9921093,0.0065010786,0.0002405395,0.0006241166,0.0002071863,0.00007318526,0.0000113928045,0.000012512042,0.0002206808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808985,0.00011026286,0.00057654316,0.00041392772,0.00060165604,0.00020774284],"domain_scores_gemma":[0.9978066,0.0011616613,0.000101521815,0.00019819803,0.0003463454,0.00038568128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019487389,0.00009626694,0.0005119863,0.00003327444,0.000062292806,0.000013815312,0.000033216216,0.00009334494,0.00002240251],"category_scores_gemma":[0.001302048,0.000056220295,0.00015715233,0.00008956463,0.00045908394,0.00002520099,0.000073001705,0.00023581853,9.94533e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012052004,0.00062254677,0.87945694,0.0001828184,0.0002639448,0.00031260238,0.00009457464,1.5512032e-7,0.00001719528,0.00032058102,0.011143581,0.10637986],"study_design_scores_gemma":[0.0033217089,0.0045380737,0.92911947,0.00013546454,0.000049664846,0.000029898047,0.00009022548,0.00006325568,0.00015562089,0.0010057698,0.061409548,0.00008132098],"about_ca_topic_score_codex":0.00005741213,"about_ca_topic_score_gemma":0.000018447978,"teacher_disagreement_score":0.106298536,"about_ca_system_score_codex":0.000021925516,"about_ca_system_score_gemma":0.00023479313,"threshold_uncertainty_score":0.2292597},"labels":[],"label_agreement":null},{"id":"W3085200587","doi":"10.1016/j.jtocrr.2020.100097","title":"Two-Year Follow-Up of a Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program","year":2020,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; Brock University; University of Calgary","funders":"Alberta Cancer Foundation; University of Calgary; Alberta Health Services","keywords":"Smoking cessation; Medicine; Lung cancer; Randomized controlled trial; Lung cancer screening; Cancer; Oncology; Environmental health; Internal medicine; Pathology","score_opus":0.1484564096100268,"score_gpt":0.49710382655003477,"score_spread":0.348647416940008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085200587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444366,0.00018367729,0.000033860873,0.00047754048,0.00012125581,0.004398162,0.0000014339568,0.000028086331,0.000312303],"genre_scores_gemma":[0.99903023,0.00013334838,0.00009175022,0.000024296174,0.000095412586,0.0005384292,0.000012158343,0.000013188875,0.00006117722],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951757,0.0010945487,0.0019128942,0.00037132233,0.0012339249,0.00021160214],"domain_scores_gemma":[0.99714947,0.0010111161,0.00052430213,0.00018689525,0.0009651854,0.00016306284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012682652,0.00010960277,0.0016153209,0.00021150749,0.000046442725,0.000022646853,0.00005127655,0.00012894232,0.00006599855],"category_scores_gemma":[0.011163783,0.00006980504,0.0002451096,0.00064027874,0.00026521806,0.00006126321,0.00006925349,0.0006672775,3.9588066e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0915235,0.000834424,0.8958079,0.000118421805,0.0002996635,0.0001643836,0.0011763937,0.000008532345,0.0001521704,0.000011133145,0.000044731954,0.009858753],"study_design_scores_gemma":[0.51836926,0.0015514839,0.46955457,0.0007385084,0.0006283927,0.000007755297,0.004612834,0.0041421456,0.00021306462,0.00005307062,0.000028610903,0.00010031562],"about_ca_topic_score_codex":0.0024290557,"about_ca_topic_score_gemma":0.00013898476,"teacher_disagreement_score":0.42684573,"about_ca_system_score_codex":0.00003074483,"about_ca_system_score_gemma":0.00029994527,"threshold_uncertainty_score":0.9971656},"labels":[],"label_agreement":null},{"id":"W3091933145","doi":"10.1016/j.jtocrr.2020.100103","title":"JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies","year":2020,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Listeria monocytogenes in Food Safety","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Johnson and Johnson; Genentech; Astellas Pharma; Eisai; Daiichi-Sankyo; Pfizer; Incyte; Pharmaceuticals Bayer; Syndax Pharmaceuticals; Clovis Oncology; Bayer Fund; AstraZeneca; Canadian Asian Studies Association; Novocure; Exelixis; Takeda Pharmaceuticals U.S.A.; Spectrum Pharmaceuticals; Merck; University of Michigan; AbbVie; Roche; Novartis; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Boehringer Ingelheim; Amgen","keywords":"Chills; Medicine; Nivolumab; Internal medicine; Gastroenterology; Combination therapy; Adverse effect; Immunotherapy; Phases of clinical research; Surgery; Cancer; Chemotherapy","score_opus":0.312419106822627,"score_gpt":0.4891006084337852,"score_spread":0.1766815016111582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091933145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475384,0.0018351084,0.00004205627,0.0016120726,0.00029418973,0.0010691909,0.00017232382,0.000034673627,0.00018656696],"genre_scores_gemma":[0.99585545,0.0009787652,0.00078894326,0.0008302542,0.000583266,0.00008952103,0.0006889737,0.000066687404,0.00011812406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468726,0.00070070854,0.0016093669,0.0015473783,0.0008138199,0.00064146094],"domain_scores_gemma":[0.9969243,0.0002983879,0.00041686764,0.0010530001,0.000890045,0.0004174352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002416289,0.0003745115,0.0007210386,0.00009243185,0.0001989961,0.000097965756,0.0003415247,0.00033487056,0.000024750998],"category_scores_gemma":[0.0015006622,0.00028097685,0.00017177539,0.00036532633,0.00079515285,0.00002104232,0.00069158827,0.00052568654,0.0000109100965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23294829,0.0032694999,0.61979043,0.00019066842,0.0021624302,0.0026399307,0.0012591324,0.00024164874,0.07764975,0.000008046905,0.006342235,0.053497937],"study_design_scores_gemma":[0.28507698,0.04164071,0.30238867,0.0011302843,0.0003071924,0.00007929103,0.001412009,0.0015235735,0.11759678,0.0004340944,0.24427839,0.0041320254],"about_ca_topic_score_codex":0.00036852824,"about_ca_topic_score_gemma":0.00019649716,"teacher_disagreement_score":0.31740177,"about_ca_system_score_codex":0.00005081389,"about_ca_system_score_gemma":0.0003800507,"threshold_uncertainty_score":0.99996424},"labels":[],"label_agreement":null},{"id":"W3115817852","doi":"10.1016/j.jtocrr.2020.100137","title":"Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria—Reducing Race Disparities","year":2020,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer screening; Cohort; Lung cancer; Demography; Population; Retrospective cohort study; Ethnic group; Task force; Race (biology); Cohort study; Cancer; Gerontology; Internal medicine; Environmental health","score_opus":0.0770495536566536,"score_gpt":0.4782571124725352,"score_spread":0.4012075588158816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115817852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98120636,0.0036881042,0.00042371763,0.012474354,0.000389103,0.0012308102,0.00020390275,0.00011610351,0.00026754677],"genre_scores_gemma":[0.98198235,0.014675861,0.0006259106,0.00039424488,0.0007658912,0.00026396333,0.00043312745,0.000035953504,0.00082266814],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9953441,0.00042048306,0.001337624,0.0012080494,0.0011529592,0.0005367757],"domain_scores_gemma":[0.996398,0.00090679986,0.0004440614,0.0005514984,0.00093467365,0.000764998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034181876,0.0002452093,0.0006593406,0.00008310515,0.00042366984,0.00014763759,0.000085190724,0.00020016951,0.00006896393],"category_scores_gemma":[0.002305878,0.00018548974,0.00021680573,0.00044374433,0.00039034017,0.0002671143,0.0003172887,0.0008907158,0.0000010288975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030023106,0.00047926485,0.9645659,0.0012500162,0.00094828114,0.0025803375,0.0013199871,0.0019485254,0.00005329393,0.00000633308,0.020096894,0.0037489047],"study_design_scores_gemma":[0.005516817,0.0020901985,0.3659932,0.0021616772,0.0012720792,0.0001911614,0.0009958162,0.60883975,0.0006220069,0.0007477207,0.011151516,0.0004180436],"about_ca_topic_score_codex":0.008635398,"about_ca_topic_score_gemma":0.00034966102,"teacher_disagreement_score":0.6068912,"about_ca_system_score_codex":0.00019100143,"about_ca_system_score_gemma":0.0004539525,"threshold_uncertainty_score":0.9979662},"labels":[],"label_agreement":null},{"id":"W3135563856","doi":"10.1016/j.jtocrr.2021.100157","title":"Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Boehringer Ingelheim; Pfizer Canada; AbbVie; Merck; AstraZeneca; Novartis; Pfizer; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Internal medicine; Alectinib; ALK inhibitor; Anaplastic lymphoma kinase; Oncology; Ceritinib; Lung cancer; Context (archaeology); Population; Hazard ratio; Brain metastasis; Gastroenterology; Cancer; Metastasis; Confidence interval; Biology","score_opus":0.052359026058187465,"score_gpt":0.4677355556769182,"score_spread":0.4153765296187307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135563856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98248845,0.00079771737,0.0000107288915,0.008169615,0.000806403,0.0017708252,0.000078096346,0.00005745519,0.0058206795],"genre_scores_gemma":[0.9752013,0.0011395715,0.0012833114,0.00023229777,0.000545539,0.00044844404,0.0001905496,0.000047900878,0.020911073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996966,0.00015585645,0.00071714714,0.0007580759,0.0009373874,0.0004655144],"domain_scores_gemma":[0.9962939,0.00053448166,0.00019709842,0.00043481318,0.0021058726,0.00043383168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013308615,0.00018528235,0.0005945061,0.00013429139,0.00035047033,0.00006708204,0.0000393064,0.00012807449,0.00019358832],"category_scores_gemma":[0.0028145157,0.00011699483,0.00016987626,0.00051255344,0.00029064956,0.00011772116,0.000087657645,0.00047656192,0.000002141898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041275457,0.00080233935,0.9658287,0.00013262374,0.0004701501,0.00032942832,0.00015986027,5.4143163e-7,0.000067352565,0.0000436326,0.021306861,0.010445742],"study_design_scores_gemma":[0.0034552887,0.0007013055,0.9591949,0.0005450843,0.0002520925,0.000008975235,0.00008625425,0.000012264565,0.0002613937,0.00015020107,0.035178017,0.00015421775],"about_ca_topic_score_codex":0.0010918466,"about_ca_topic_score_gemma":0.0015824466,"teacher_disagreement_score":0.015090395,"about_ca_system_score_codex":0.0003792646,"about_ca_system_score_gemma":0.0009225096,"threshold_uncertainty_score":0.47709107},"labels":[],"label_agreement":null},{"id":"W3152584524","doi":"10.1016/j.jtocrr.2021.100169","title":"High-Grade Neuroendocrine Carcinoma Within a Tracheal Polyp: A Case Report","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Pfizer Canada; Bristol-Myers Squibb Canada; Merck Canada; EMD Serono; Canada Foundation for Innovation; AstraZeneca; Bristol-Myers Squibb; Fondation de l'Hôpital Général de Montréal; Roche; Merck; Amgen Canada; Amgen","keywords":"Pathology; Immunohistochemistry; Pathogenesis; Biology; Carcinoma; Neuroendocrine tumors; Lesion; Medicine","score_opus":0.15808050372146534,"score_gpt":0.45925105727589355,"score_spread":0.30117055355442823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152584524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98424387,0.0014516516,0.0000021376263,0.012093688,0.0005763842,0.00047216847,0.000007409592,0.000056097746,0.001096606],"genre_scores_gemma":[0.99417263,0.00030264046,0.0005288911,0.00043611342,0.0007251796,0.00008520743,0.00006409083,0.000031714706,0.0036535573],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9955667,0.00044746997,0.0013835974,0.0009917102,0.001046551,0.0005639273],"domain_scores_gemma":[0.99664366,0.0007890165,0.00019362343,0.0008907616,0.00054461346,0.0009383322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025977755,0.00020357563,0.00069932156,0.00012255761,0.00025476314,0.0000718579,0.00003889395,0.00009897826,0.00017650393],"category_scores_gemma":[0.0041978885,0.00013805227,0.00025516775,0.00038959368,0.0003897994,0.000062529885,0.00019756773,0.0009642371,0.000012818674],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008817132,0.001147518,0.44433677,0.000048660324,0.00005982184,0.5510184,0.00002788355,2.3042679e-7,0.000018893386,0.000113589376,0.002213399,0.00092664495],"study_design_scores_gemma":[0.0013695006,0.000773653,0.38278285,0.000050527906,0.000096054064,0.6100186,0.00010983098,0.00002301529,0.0014501273,0.0005802039,0.0026501804,0.00009546251],"about_ca_topic_score_codex":0.0020360546,"about_ca_topic_score_gemma":0.00019773527,"teacher_disagreement_score":0.061553918,"about_ca_system_score_codex":0.00004901914,"about_ca_system_score_gemma":0.0006711141,"threshold_uncertainty_score":0.56296086},"labels":[],"label_agreement":null},{"id":"W3175514092","doi":"10.1016/j.jtocrr.2021.100205","title":"Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"Janssen Pharmaceuticals; Loxo Oncology; Chugai Pharmaceutical; Genentech; Free Market Institute, Texas Tech University; National Institutes of Health; Shire; Bayer Fund; Mirati Therapeutics; Clovis Oncology; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Verily Life Sciences; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; AbbVie; ACEA Biosciences; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Sanofi; EMD Serono; Mesothelioma Applied Research Foundation; Heron Therapeutics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Pfizer; Boehringer Ingelheim; Amgen; Roche","keywords":"Pembrolizumab; Medicine; Brain metastasis; Internal medicine; Chemotherapy; Lung cancer; Oncology; Confidence interval; Metastasis; Adverse effect; Cancer; Immunotherapy","score_opus":0.042763170746134116,"score_gpt":0.40124649074367263,"score_spread":0.3584833199975385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175514092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580085,0.0008509588,0.00003146217,0.0020624772,0.00001984898,0.0010095979,0.000027496139,0.000016166061,0.00018116363],"genre_scores_gemma":[0.9977393,0.0003807587,0.0006620489,0.00036493287,0.000019781959,0.000063230524,0.00012651809,0.000028330736,0.0006151093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963225,0.00042271972,0.00088407745,0.00073678355,0.0011951979,0.00043873413],"domain_scores_gemma":[0.9972173,0.0007883341,0.00028116867,0.0005100145,0.00091077056,0.00029240243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024721469,0.00023724424,0.0011483404,0.0003963906,0.00010150087,0.00006716058,0.000055978144,0.00014483756,0.000046661928],"category_scores_gemma":[0.0004376344,0.00012531152,0.00014822673,0.0014134457,0.0008425505,0.00010186693,0.000060046874,0.0004716675,2.2416557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030869788,0.0016085157,0.93569744,0.00008571864,0.0058465283,0.0017440864,0.00024135178,0.000001986853,0.00010203125,0.000009075253,0.00007167624,0.0237218],"study_design_scores_gemma":[0.016547302,0.0049267714,0.9755144,0.00032497648,0.0009413733,0.000093740244,0.00025512392,0.000032496035,0.00048884656,0.000028199986,0.0006617074,0.00018502431],"about_ca_topic_score_codex":0.00097307283,"about_ca_topic_score_gemma":0.0015599431,"teacher_disagreement_score":0.039816994,"about_ca_system_score_codex":0.000053569973,"about_ca_system_score_gemma":0.000550615,"threshold_uncertainty_score":0.5110055},"labels":[],"label_agreement":null},{"id":"W3181684306","doi":"10.1016/j.jtocrr.2021.100212","title":"A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Kingston Health Sciences Centre; London Health Sciences Centre; University of Calgary; University Health Network; Ottawa Hospital; Université Laval; Centre Hospitalier de l’Université de Montréal; Hamilton Regional Laboratory Medicine Program; Queen Elizabeth II Health Sciences Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Trillium Health Centre; AstraZeneca (Canada); McMaster University; Dalhousie University; Hamilton Health Sciences; Western University; University of Toronto","funders":"Roche; AstraZeneca Canada; AstraZeneca; Pfizer","keywords":"T790M; Concordance; Digital polymerase chain reaction; Mutation; Medicine; Resistance mutation; Polymerase chain reaction; Oncology; Internal medicine; Biology; Genetics; Gene; KRAS; Reverse transcriptase","score_opus":0.17087415249630863,"score_gpt":0.5011210858427947,"score_spread":0.330246933346486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181684306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997197,0.00041446203,0.00041920305,0.00055016263,0.00020873852,0.0010576461,0.0000116708125,0.00000838011,0.00013275864],"genre_scores_gemma":[0.9989017,0.000022686358,0.00045668022,0.000046189944,0.0002814242,0.00008256475,0.000038943985,0.000011568435,0.00015819204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983892,0.000188576,0.0005268937,0.00029989044,0.00041806002,0.00017739777],"domain_scores_gemma":[0.9980266,0.0006615309,0.00013514717,0.00023028994,0.0007995882,0.0001468293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016126868,0.00006487477,0.00019813601,0.000062572566,0.00034215572,0.00005529723,0.000021393282,0.00005686022,0.000036613743],"category_scores_gemma":[0.0024765693,0.000043140313,0.000089741916,0.00021638586,0.0000950194,0.00006984855,0.000024176195,0.0001884731,3.8304546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020306063,0.001500793,0.8564054,0.00012890063,0.0013444732,0.00284358,0.002525195,0.00006921713,0.023676941,0.00002567535,0.000046595855,0.1112302],"study_design_scores_gemma":[0.0027137478,0.0010562214,0.97673786,0.00014270381,0.0009893589,0.00043975256,0.005164211,0.0039310367,0.0068080337,0.0011947834,0.0007216794,0.00010064308],"about_ca_topic_score_codex":0.029054593,"about_ca_topic_score_gemma":0.012440236,"teacher_disagreement_score":0.12033246,"about_ca_system_score_codex":0.00009677183,"about_ca_system_score_gemma":0.0010245522,"threshold_uncertainty_score":0.97741103},"labels":[],"label_agreement":null},{"id":"W3208513157","doi":"10.1016/j.jtocrr.2021.100251","title":"Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Takeda Canada; Bristol-Myers Squibb Canada; EMD Serono; Amgen; Boehringer Ingelheim; Meso Scale Diagnostics; Sanofi; Roche; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Hazard ratio; Stage (stratigraphy); Adverse effect; Incidence (geometry); Chemotherapy; Oncology; Cancer; Confidence interval; Immunotherapy","score_opus":0.0722457016137158,"score_gpt":0.42115690683150875,"score_spread":0.34891120521779295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208513157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996147,0.0007948557,0.000018465205,0.00093738927,0.000091406466,0.00085174857,0.0000059188046,0.000017426251,0.0011358288],"genre_scores_gemma":[0.9928088,0.0014033666,0.00010364587,0.00011748668,0.000083007,0.000024099796,0.0000481139,0.000019167717,0.00539227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715275,0.00024363254,0.0006860493,0.0005765918,0.00097519107,0.00036579254],"domain_scores_gemma":[0.9982521,0.00044273926,0.00014991747,0.0003333836,0.00055076723,0.00027111493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027086816,0.00014181026,0.0005029877,0.00009458458,0.00013722619,0.00006884186,0.00003764871,0.00012929937,0.00017104365],"category_scores_gemma":[0.0008534254,0.00007929781,0.00004231643,0.00047291024,0.00051884627,0.00010260628,0.000073210285,0.0005723323,9.20918e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019972235,0.00088634755,0.83100665,0.0001533959,0.00013328549,0.0013370095,0.00018755291,8.85912e-7,0.000076885575,0.0000061275746,0.00027561068,0.14596401],"study_design_scores_gemma":[0.02304659,0.0044114743,0.9397065,0.0006366442,0.00003464828,0.00018790641,0.0002595759,0.000078052275,0.0002256545,0.000006549565,0.031239402,0.0001669898],"about_ca_topic_score_codex":0.00050248706,"about_ca_topic_score_gemma":0.0010864864,"teacher_disagreement_score":0.14579701,"about_ca_system_score_codex":0.00008094485,"about_ca_system_score_gemma":0.0009963036,"threshold_uncertainty_score":0.3233671},"labels":[],"label_agreement":null},{"id":"W3211244077","doi":"10.1016/j.jtocrr.2021.100249","title":"A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Kingston Health Sciences Centre; University of Calgary","funders":"","keywords":"Atezolizumab; Medicine; Etoposide; Hazard ratio; Oncology; Internal medicine; Chemotherapy; Carboplatin; Confidence interval; Cisplatin; Cancer; Pembrolizumab; Immunotherapy","score_opus":0.12703755635832875,"score_gpt":0.4785684825184646,"score_spread":0.35153092616013587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211244077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927102,0.00040722903,3.467625e-7,0.0018503352,0.00007058772,0.0011459845,0.0000065812883,0.0000052602213,0.0038035233],"genre_scores_gemma":[0.9975024,0.0008347522,0.00011692164,0.00010121866,0.000057286652,0.00007377245,0.000022068345,0.000017810107,0.0012737574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941136,0.0005989898,0.00097446475,0.00056275685,0.0032747078,0.00047546788],"domain_scores_gemma":[0.99548775,0.00071353366,0.00017211505,0.00047799316,0.0029091763,0.0002394197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058900514,0.0001259502,0.0006400151,0.00018194635,0.00005674696,0.000014100924,0.000054442036,0.000068547546,0.0001251036],"category_scores_gemma":[0.005502391,0.000088204826,0.000045984387,0.0008605919,0.00034134387,0.000063405896,0.00015428904,0.0007275033,5.9194326e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015012299,0.00027693372,0.9813895,0.00017654191,0.00007795737,0.002243264,0.00016217107,0.0000327259,0.000033617387,0.00001041841,0.00106162,0.013033992],"study_design_scores_gemma":[0.006937295,0.00042585772,0.9897969,0.0005984284,0.000017834192,0.000012162074,0.0003348527,0.0005169248,0.00033177668,0.00016383357,0.00077368977,0.000090444766],"about_ca_topic_score_codex":0.6084371,"about_ca_topic_score_gemma":0.91091675,"teacher_disagreement_score":0.3024796,"about_ca_system_score_codex":0.0014749059,"about_ca_system_score_gemma":0.01336999,"threshold_uncertainty_score":0.99222326},"labels":[],"label_agreement":null},{"id":"W4200254289","doi":"10.1016/j.jtocrr.2021.100269","title":"Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Foundation Medicine; Genentech; Merck Sharp and Dohme; Eli Lilly and Company; Ono Pharmaceutical; Daiichi-Sankyo; BeiGene; TG Therapeutics; Regeneron Pharmaceuticals; Johnson and Johnson; Takeda Pharmaceutical Company; Amgen; Boehringer Ingelheim; Chugai Pharmaceutical; Roche; Novartis; Sanofi; Merck; Pfizer; G1 Therapeutics; Daiichi Sankyo Europe; Bayer; AstraZeneca; Bristol-Myers Squibb","keywords":"Lung cancer; Medicine; Clinical trial; Cancer; Disease; Pandemic; Internal medicine; Oncology; Intensive care medicine; Family medicine; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty)","score_opus":0.24571517747603738,"score_gpt":0.6083806683625385,"score_spread":0.3626654908865011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200254289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404081,0.00572953,0.0000049144714,0.051079765,0.00078059285,0.0015620947,0.00021995923,0.000017528248,0.00019747618],"genre_scores_gemma":[0.9809598,0.012194379,0.000022781456,0.004508619,0.0007134197,0.00035960833,0.000018062354,0.000025695625,0.001197669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942555,0.001344114,0.0015658343,0.00088043505,0.0014316613,0.00052248145],"domain_scores_gemma":[0.9945024,0.0023105298,0.00039436156,0.00090238644,0.0007548955,0.0011354192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067222533,0.00022974252,0.0011635341,0.00004377033,0.00014971096,0.0000533627,0.00011957404,0.0001702575,0.0006197733],"category_scores_gemma":[0.004343461,0.00010890291,0.0007022858,0.00049940264,0.00036616685,0.00005122779,0.0002455379,0.0006763542,0.000003872157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002921139,0.00097325305,0.79709166,0.00015116301,0.0009598705,0.00083697896,0.000037577905,0.000050067305,0.000006318759,0.0000060845136,0.18669435,0.010271558],"study_design_scores_gemma":[0.0027331929,0.0009213715,0.9843661,0.0017171782,0.00071265455,0.00005948054,0.000027675698,0.000092398615,0.00001517349,0.00003895272,0.009181236,0.00013456275],"about_ca_topic_score_codex":0.008069713,"about_ca_topic_score_gemma":0.00499998,"teacher_disagreement_score":0.18727449,"about_ca_system_score_codex":0.0006999785,"about_ca_system_score_gemma":0.0043196576,"threshold_uncertainty_score":0.99853563},"labels":[],"label_agreement":null},{"id":"W4200545467","doi":"10.1016/j.jtocrr.2021.100259","title":"Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Ethnic group; Confidence interval; Oncology; Subgroup analysis","score_opus":0.03152248506292136,"score_gpt":0.4202601434878151,"score_spread":0.3887376584248937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200545467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997484,0.00029758504,0.00000549819,0.0006381484,0.000049429207,0.0007309544,0.000014631351,0.000011249795,0.00076850166],"genre_scores_gemma":[0.9986555,0.00015305552,0.00013062921,0.00003041431,0.000043015214,0.00003412333,0.0000780271,0.000013670195,0.00086158374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978431,0.00028018022,0.0005063474,0.00039829058,0.0007896666,0.00018242106],"domain_scores_gemma":[0.9969231,0.0011980166,0.00018495486,0.00020179545,0.0012710072,0.00022114547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000619162,0.00012164263,0.0004681191,0.00011415274,0.000102382786,0.000013063316,0.000015355208,0.00011327017,0.000011611096],"category_scores_gemma":[0.0010669196,0.00006631089,0.00006459541,0.00036868686,0.00051960896,0.00006166936,0.00004011568,0.00030221973,3.882034e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031335524,0.0022165854,0.9820524,0.0002522378,0.00041163544,0.003546723,0.00015154603,0.000002449965,0.00011634597,0.000043593373,0.0000992209,0.007973743],"study_design_scores_gemma":[0.0057941577,0.0062913513,0.9737002,0.0005934587,0.00023214048,0.00007770272,0.000074846575,0.000005380655,0.012966149,0.000060089915,0.00013346228,0.000071061215],"about_ca_topic_score_codex":0.00043679544,"about_ca_topic_score_gemma":0.0000951633,"teacher_disagreement_score":0.012849803,"about_ca_system_score_codex":0.000057837737,"about_ca_system_score_gemma":0.00027165195,"threshold_uncertainty_score":0.27040794},"labels":[],"label_agreement":null},{"id":"W4205889660","doi":"10.1016/j.jtocrr.2022.100283","title":"Brief Report: Medical Assistance in Dying in Patients With Lung Cancer","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Cancer; Internal medicine; Referral; Population; Systemic therapy; Cancer registry; Oncology; Breast cancer; Family medicine","score_opus":0.07544225536086939,"score_gpt":0.5058288438690641,"score_spread":0.4303865885081947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205889660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850642,0.0021115397,0.000002044452,0.0089315465,0.00023006575,0.0010721337,0.000004366062,0.000022914026,0.002561185],"genre_scores_gemma":[0.9961101,0.00067300536,0.000048345843,0.00030880971,0.00016506793,0.00057692867,0.000015452495,0.000024805933,0.0020775183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917285,0.00061715365,0.0012073616,0.0008713389,0.0048306296,0.00074503385],"domain_scores_gemma":[0.99754477,0.0007531829,0.00018001707,0.00052419526,0.0005035315,0.0004943142],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014135068,0.00013874451,0.00060353096,0.00031034378,0.00026280808,0.00003211315,0.00012769362,0.00010818185,0.00048771768],"category_scores_gemma":[0.008581064,0.00009732312,0.000062012754,0.0010048117,0.0007189625,0.000086940745,0.0008050758,0.0026455503,6.572813e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011360482,0.0007053637,0.94668984,0.00017568299,0.000067157394,0.037749782,0.00015031513,0.0000056938134,0.0000016979851,0.000012274395,0.0066694967,0.006636642],"study_design_scores_gemma":[0.0029434592,0.0006008358,0.9726916,0.00045370712,0.000010849238,0.00024421373,0.00012228992,0.00019253851,0.0000025185816,0.000089444,0.022530315,0.00011823115],"about_ca_topic_score_codex":0.0024124838,"about_ca_topic_score_gemma":0.0019143721,"teacher_disagreement_score":0.037505567,"about_ca_system_score_codex":0.00062217587,"about_ca_system_score_gemma":0.0020957952,"threshold_uncertainty_score":0.9997701},"labels":[],"label_agreement":null},{"id":"W4205902408","doi":"10.1016/j.jtocrr.2022.100276","title":"Performance of an RNA-Based Next-Generation Sequencing Assay for Combined Detection of Clinically Actionable Fusions and Hotspot Mutations in NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Fonds de Recherche du Québec - Santé; Pfizer Canada; AstraZeneca; Bayer; Novartis; Pfizer; Eli Lilly and Company","keywords":"Computational biology; DNA sequencing; RNA; Multiplex; Housekeeping gene; Biology; Gene; Bioinformatics; Genetics; Gene expression","score_opus":0.12853710544670857,"score_gpt":0.4045420364913926,"score_spread":0.27600493104468404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205902408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988701,0.00010067771,0.0002928775,0.00015520901,0.00014472935,0.0003462453,0.000023151746,0.0000022346624,0.00006477859],"genre_scores_gemma":[0.9985239,0.0002797293,0.00075432914,0.00004308059,0.000120393335,0.000102218415,0.00010779523,0.000008221062,0.0000603466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984783,0.00020750135,0.0006796309,0.00028257797,0.00021818346,0.00013379657],"domain_scores_gemma":[0.9988243,0.00038334008,0.0002009359,0.0001921664,0.0003187927,0.000080441205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045482335,0.00005632779,0.00015748185,0.00008408954,0.0002053967,0.0000135227,0.00004718818,0.00008834028,0.0000068817626],"category_scores_gemma":[0.0021941199,0.000053531287,0.00005295174,0.00012732834,0.00017946515,0.000007900617,0.000099035096,0.00018230292,3.6533965e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008420459,0.00037554238,0.041141108,0.000066694294,0.000021008187,0.000009126575,0.000041361207,0.0036780233,0.9290202,0.00002374369,0.00011622739,0.024664912],"study_design_scores_gemma":[0.006476968,0.026982754,0.16178302,0.0000974175,0.00008738122,0.00011214089,0.0011982708,0.3501753,0.44026047,0.0017328622,0.010507713,0.000585687],"about_ca_topic_score_codex":0.00016170915,"about_ca_topic_score_gemma":0.00023353456,"teacher_disagreement_score":0.48875973,"about_ca_system_score_codex":0.00002576663,"about_ca_system_score_gemma":0.00048914045,"threshold_uncertainty_score":0.26267248},"labels":[],"label_agreement":null},{"id":"W4214510639","doi":"10.1016/j.jtocrr.2022.100304","title":"Trends of Molecular Testing for Lung Cancer at the King Faisal Hospital, Kigali: Therapeutic and Survival Implications","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Lung cancer; Cancer; Carboplatin; Internal medicine; Oncology; Stage (stratigraphy); Biomarker; Targeted therapy; Disease; Chemotherapy; Biology","score_opus":0.155052970415355,"score_gpt":0.5397272122547654,"score_spread":0.38467424183941035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214510639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97706395,0.0051265787,0.00006873153,0.015080325,0.00020313908,0.000716198,0.00004410016,0.000015433581,0.0016815688],"genre_scores_gemma":[0.99705863,0.00015628045,0.00013372966,0.00013796483,0.000089892565,0.00059109053,0.000022496153,0.000014079043,0.001795834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998597,0.00012198934,0.00038329285,0.00029456467,0.000398964,0.00020414285],"domain_scores_gemma":[0.99822253,0.0009806262,0.00012522575,0.000253442,0.0003061687,0.00011202472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016347958,0.00006739113,0.00019761526,0.00006194656,0.0005469717,0.000017969507,0.000041805783,0.000033933593,0.00005872772],"category_scores_gemma":[0.00061399664,0.00004118307,0.00007995666,0.0002870292,0.00036535828,0.000022539454,0.00017228935,0.00023098217,5.592456e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071655086,0.00025258216,0.9179337,0.00007280208,0.0003101322,0.000061926214,0.00026709354,0.000022728662,0.0017166265,0.0005116777,0.0017375131,0.07704154],"study_design_scores_gemma":[0.0014869471,0.0015327353,0.9623065,0.00006622642,0.00045988546,0.00014307255,0.0004455228,0.00064783456,0.00027428553,0.0015301952,0.030983152,0.00012362456],"about_ca_topic_score_codex":0.0004140252,"about_ca_topic_score_gemma":0.00004061411,"teacher_disagreement_score":0.07691791,"about_ca_system_score_codex":0.00007264202,"about_ca_system_score_gemma":0.00028203815,"threshold_uncertainty_score":0.4206919},"labels":[],"label_agreement":null},{"id":"W4220684825","doi":"10.1016/j.jtocrr.2022.100316","title":"Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Medicine; Toxicity; Internal medicine; Regimen; Cohort; Chemoradiotherapy; Log-rank test; Cisplatin; Proportional hazards model; Overall survival; Surgery; Chemotherapy; Cancer","score_opus":0.145011355453734,"score_gpt":0.48796667512408687,"score_spread":0.34295531967035287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220684825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913979,0.0011886046,0.00016653133,0.0030794223,0.00028539944,0.0018481502,0.00001773433,0.00005006572,0.0019661752],"genre_scores_gemma":[0.99472475,0.0002445553,0.00085867505,0.00013033581,0.00014379331,0.0002926149,0.00013237566,0.00003616537,0.0034367198],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960921,0.00025937514,0.0013799827,0.00064517057,0.0012408112,0.0003825935],"domain_scores_gemma":[0.9969691,0.0008319061,0.0005634406,0.00059148355,0.0008265718,0.00021750176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005197947,0.00016368908,0.0008136299,0.00015270479,0.00032193822,0.000026289676,0.00008858171,0.00012232752,0.00018678866],"category_scores_gemma":[0.0011478706,0.00012277006,0.00021048119,0.0005019185,0.00079004216,0.00006710205,0.00007614129,0.00054871273,3.9075496e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28190672,0.0043683127,0.40693983,0.0004888891,0.0016483862,0.004001714,0.00046951862,0.000037494112,0.019246923,0.00006683735,0.025296493,0.25552887],"study_design_scores_gemma":[0.067334,0.069513276,0.24572481,0.00058907404,0.00041741494,0.005163119,0.0033355895,0.0014787065,0.017577384,0.00024138026,0.58782613,0.0007991136],"about_ca_topic_score_codex":0.0002736394,"about_ca_topic_score_gemma":0.000042529606,"teacher_disagreement_score":0.5625296,"about_ca_system_score_codex":0.00015468248,"about_ca_system_score_gemma":0.0010530079,"threshold_uncertainty_score":0.50064176},"labels":[],"label_agreement":null},{"id":"W4224212079","doi":"10.1016/j.jtocrr.2022.100300","title":"The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma","year":2022,"lang":"en","type":"letter","venue":"JTO Clinical and Research Reports","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Pemetrexed; Mesothelioma; Medicine; Carboplatin; Oncology; Scopus; Internal medicine; Chemotherapy; Cisplatin; Intensive care medicine; MEDLINE; Pathology","score_opus":0.16623406221225365,"score_gpt":0.4769155864162436,"score_spread":0.31068152420399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224212079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60322464,0.004410768,7.538424e-8,0.38136986,0.00039673367,0.0023115422,0.000086963686,0.000026755923,0.00817266],"genre_scores_gemma":[0.8147177,0.018823838,0.000064383516,0.046766825,0.0033367856,0.0010740806,0.0004123844,0.00008905558,0.11471494],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99540037,0.00047429526,0.0011457588,0.0006534683,0.0018601655,0.00046592188],"domain_scores_gemma":[0.99643713,0.0023538633,0.00022647195,0.00061930163,0.00009268723,0.00027055663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029342824,0.0001953788,0.00057019223,0.0002511335,0.00018686167,0.000032022694,0.00015254968,0.00016776449,0.0006714031],"category_scores_gemma":[0.0010648347,0.000106101266,0.00024411909,0.00032402357,0.0005324232,0.00004747048,0.00036482778,0.0009876868,0.000019097855],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008766113,0.00035254867,0.8045255,0.00010848654,0.00009754487,0.0075375843,0.00003681787,0.0000011077694,0.00004717255,0.000011357875,0.17045058,0.015954668],"study_design_scores_gemma":[0.00017182303,0.0019630468,0.37369913,0.00017365953,0.00004298984,0.00007365938,0.00003976528,0.0000038286707,0.00005307218,0.00037198985,0.6233297,0.0000773358],"about_ca_topic_score_codex":0.0031888394,"about_ca_topic_score_gemma":0.00064416847,"teacher_disagreement_score":0.4528791,"about_ca_system_score_codex":0.0002498167,"about_ca_system_score_gemma":0.00052129134,"threshold_uncertainty_score":0.73513925},"labels":[],"label_agreement":null},{"id":"W4225123144","doi":"10.1016/j.jtocrr.2022.100332","title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Janssen Pharmaceuticals; NIHR Leicester Clinical Research Facility; Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; EMD Serono; Genentech; Daiichi-Sankyo; National Institute for Health and Care Research; Exelixis; Kissei; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Comprehensive Cancer Center, City of Hope; Merck KGaA; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; Bayer; Gilead Sciences; Roche; Novartis; Kyowa Hakko Kirin; Sanofi; Manchester Biomedical Research Centre; Yuhan; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company","keywords":"ROS1; Medicine; Term (time); Oncology; Internal medicine; Cancer; Adenocarcinoma; Physics","score_opus":0.07867063295629535,"score_gpt":0.49609754518857463,"score_spread":0.4174269122322793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225123144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992036,0.0010261765,0.000002655806,0.0019338084,0.0001382354,0.0007283598,0.000012163025,0.000009149564,0.0041134865],"genre_scores_gemma":[0.99663967,0.00084526796,0.00004839249,0.000074226205,0.00007360175,0.000047768917,0.00003354796,0.000008452903,0.0022290645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805117,0.00026141913,0.00057584856,0.00034657112,0.0005594965,0.0002055239],"domain_scores_gemma":[0.9985562,0.00078455516,0.00009812289,0.00020264661,0.00016421122,0.00019425835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021792825,0.00006949155,0.00029257868,0.00012337024,0.00019290356,0.000010426636,0.000028189936,0.00005200447,0.00023764512],"category_scores_gemma":[0.0008893579,0.000050164912,0.000056993817,0.0002494016,0.0002824579,0.000029896364,0.00023377984,0.00048521697,9.892992e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011665958,0.0011608002,0.9169242,0.000053857562,0.00010239604,0.0028073257,0.0005984996,0.0000018250262,0.0001403982,0.00005107087,0.00049449806,0.07649854],"study_design_scores_gemma":[0.002707997,0.0012019222,0.9925543,0.00012378024,0.00004730992,0.00034780713,0.00019747432,0.000009116972,0.00007668775,0.00015537196,0.002528021,0.0000502131],"about_ca_topic_score_codex":0.00025382199,"about_ca_topic_score_gemma":0.00006131611,"teacher_disagreement_score":0.07644833,"about_ca_system_score_codex":0.000070817776,"about_ca_system_score_gemma":0.0003262407,"threshold_uncertainty_score":0.26020473},"labels":[],"label_agreement":null},{"id":"W4225994592","doi":"10.1016/j.jtocrr.2022.100324","title":"Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Roche; Novartis; Amgen; Pfizer; Les Laboratories Pierre Fabre; Novartis Pharmaceuticals Corporation; AstraZeneca; Takeda Pharmaceutical Company; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Hazard ratio; Medicine; Trametinib; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Vemurafenib; Cancer","score_opus":0.07276526832441786,"score_gpt":0.4439244341244604,"score_spread":0.37115916580004255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225994592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959848,0.00012512863,0.00000427241,0.00014386338,0.00064392673,0.0016007582,0.00006332901,0.000012367962,0.0014215317],"genre_scores_gemma":[0.99838716,0.00023010664,0.00046315242,0.00005431738,0.0001573742,0.00014494985,0.00023471894,0.000036422418,0.00029179815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99252796,0.0019661577,0.002544488,0.0011606567,0.0012300753,0.00057067233],"domain_scores_gemma":[0.996719,0.0010906153,0.00054795167,0.0008009945,0.000498845,0.00034258465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008616886,0.00024306032,0.0011213626,0.00020475943,0.00012972664,0.000023430672,0.00025922217,0.000277541,0.000034656132],"category_scores_gemma":[0.0035126,0.00016985279,0.00026251454,0.00051723357,0.00081920915,0.000011931814,0.0005255151,0.0013650707,6.812807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25438172,0.0010069167,0.7291397,0.000032844124,0.00009501312,0.00048599677,0.000052001837,0.00002824847,0.00000928672,0.00001786754,0.00018733156,0.014563078],"study_design_scores_gemma":[0.12106628,0.054445207,0.8094368,0.00007311909,0.000034147146,0.0000070775613,0.00045371405,0.0000076004258,0.00008166847,0.00004487597,0.014036227,0.00031326362],"about_ca_topic_score_codex":0.00020488653,"about_ca_topic_score_gemma":0.004069986,"teacher_disagreement_score":0.13331543,"about_ca_system_score_codex":0.00006764654,"about_ca_system_score_gemma":0.0014844054,"threshold_uncertainty_score":0.6926396},"labels":[],"label_agreement":null},{"id":"W4280525579","doi":"10.1016/j.jtocrr.2022.100340","title":"Automating Access to Real-World Evidence","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; Open Society Institute; Roche","keywords":"Concordance; Artificial intelligence; Gold standard (test); Data extraction; Computer science; Medicine; Natural language processing; Data collection; Machine learning; MEDLINE; Internal medicine; Statistics","score_opus":0.8253776973697489,"score_gpt":0.7123081539362991,"score_spread":0.11306954343344977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280525579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94356686,0.00020746063,0.000012571655,0.050024424,0.0007209742,0.0007054411,6.51725e-7,0.000054480417,0.0047071124],"genre_scores_gemma":[0.99024844,0.00041205515,0.0002741642,0.0014872492,0.0007184117,0.00020436765,0.0000037672037,0.000011641322,0.0066398764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656725,0.0004637564,0.0009630801,0.00047537155,0.0011498341,0.00038073704],"domain_scores_gemma":[0.996272,0.0020286904,0.00011916842,0.00043879097,0.0005838005,0.00055753184],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012888228,0.00006775002,0.00023709747,0.00023988818,0.0006431918,0.00007885199,0.000119065444,0.000048391812,0.00065197394],"category_scores_gemma":[0.011827237,0.00005480142,0.00006572066,0.00086300046,0.0001641742,0.0001296192,0.0005445553,0.0009101776,0.000029806735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012637414,0.00015852207,0.7869913,0.00008746118,0.000008868562,0.0005046095,0.00034663134,0.000006823639,0.000082912986,0.00006832311,0.0354742,0.17614397],"study_design_scores_gemma":[0.000030173413,0.0015213342,0.9004965,0.0004259945,0.000019052419,0.00031931567,0.0011216769,0.00049348763,0.0007894438,0.006270879,0.08835566,0.00015649252],"about_ca_topic_score_codex":0.005915111,"about_ca_topic_score_gemma":0.00050672295,"teacher_disagreement_score":0.17598748,"about_ca_system_score_codex":0.000145555,"about_ca_system_score_gemma":0.00094864075,"threshold_uncertainty_score":0.99649656},"labels":[],"label_agreement":null},{"id":"W4281720443","doi":"10.1016/j.jtocrr.2022.100350","title":"Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; Alberta Health Services; University of Alberta; University of Calgary; Alberta Health","funders":"","keywords":"Medicine; Medical prescription; Lung cancer screening; Stage (stratigraphy); Lung cancer; Computed tomography; Health care; Cost–benefit analysis; Emergency medicine; Intensive care medicine; Radiology; Internal medicine","score_opus":0.06801608925398014,"score_gpt":0.4345918053243477,"score_spread":0.36657571607036754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281720443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98579454,0.002488352,0.000010024998,0.009053263,0.0004944281,0.0017876467,0.000111779395,0.000017841463,0.00024211517],"genre_scores_gemma":[0.9964498,0.00025991985,0.00022776317,0.0006018771,0.00029613296,0.0014126773,0.00015562898,0.000024886038,0.0005712583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968546,0.00021389284,0.00075282645,0.0006925796,0.0009860498,0.0005000417],"domain_scores_gemma":[0.99705863,0.0017285204,0.00014485022,0.0003487297,0.00028512182,0.0004341558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014488653,0.00014349468,0.0005038885,0.00015494341,0.00032915958,0.000034282373,0.00008268082,0.00007132277,0.00032596776],"category_scores_gemma":[0.0005881629,0.00011491536,0.00014124505,0.0005090547,0.00014760172,0.00003755653,0.00023001689,0.00062893896,1.2187706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005471327,0.0004628595,0.9373474,0.00007466066,0.00024580347,0.0016613302,0.00012184859,0.000050178198,0.000013225254,0.000008208259,0.042215977,0.017251376],"study_design_scores_gemma":[0.003330702,0.00039837766,0.9564257,0.00041235777,0.00007788368,0.000035653098,0.00020882598,0.0027923416,0.00008037719,0.00007162378,0.036009178,0.00015692686],"about_ca_topic_score_codex":0.9000334,"about_ca_topic_score_gemma":0.82906604,"teacher_disagreement_score":0.07096738,"about_ca_system_score_codex":0.0005777045,"about_ca_system_score_gemma":0.0017818533,"threshold_uncertainty_score":0.46861124},"labels":[],"label_agreement":null},{"id":"W4282843614","doi":"10.1016/j.jtocrr.2022.100356","title":"Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University of Alberta","funders":"","keywords":"BAP1; Mesothelioma; Germline; Peritoneal mesothelioma; Germline mutation; Medicine; Pleural cavity; Pathology; In situ; Cancer research; Mutation; Biology; Surgery; Genetics; Gene; Chemistry","score_opus":0.06862817006105591,"score_gpt":0.41371990197638775,"score_spread":0.3450917319153318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282843614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957839,0.00043421047,5.631555e-7,0.0022707027,0.000069297275,0.00056903914,0.000020056725,0.000024554483,0.0008276573],"genre_scores_gemma":[0.9974162,0.00004537946,0.00006893828,0.00020425535,0.00011523815,0.000120928366,0.00016617666,0.000022697277,0.0018401924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642056,0.00044496258,0.00096969755,0.00064055796,0.0011381009,0.00038609002],"domain_scores_gemma":[0.99864596,0.00047172775,0.00017394497,0.00025950777,0.00009522258,0.00035363424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003671279,0.00015708573,0.0004338599,0.00031461584,0.00023240736,0.000036244863,0.000041428128,0.00009874889,0.00018828284],"category_scores_gemma":[0.0011457797,0.0001154277,0.00007635138,0.00053352833,0.00048237777,0.0001091216,0.00025022897,0.0007039019,0.0000021359922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007565646,0.00070672494,0.54317254,0.00003011441,0.000035379602,0.4535774,0.00014420906,0.000009733118,0.0003538862,0.0000046241094,0.00016789508,0.0010409157],"study_design_scores_gemma":[0.0019323668,0.0011389757,0.881953,0.00008094734,0.000029825262,0.112978615,0.0004368712,0.00022694672,0.00007341135,0.000302686,0.0007050491,0.00014127843],"about_ca_topic_score_codex":0.0005982594,"about_ca_topic_score_gemma":0.0009696629,"teacher_disagreement_score":0.3405988,"about_ca_system_score_codex":0.00015800016,"about_ca_system_score_gemma":0.00025575052,"threshold_uncertainty_score":0.4707005},"labels":[],"label_agreement":null},{"id":"W4283463957","doi":"10.1016/j.jtocrr.2022.100371","title":"Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; Positive Living North; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Radiation therapy; Oncology; Palliative care; Lung cancer; Cohort","score_opus":0.07884287066603579,"score_gpt":0.43111608636681875,"score_spread":0.35227321570078296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283463957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927867,0.0003081578,0.000096819815,0.004014958,0.00012974886,0.0022183172,0.00003935915,0.000024215946,0.0003817162],"genre_scores_gemma":[0.9968351,0.00013321605,0.00024157975,0.000519895,0.00010952191,0.00075936184,0.00031536573,0.000019984114,0.0010659577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99512714,0.0011664565,0.0011413002,0.00056674954,0.0015787976,0.00041956693],"domain_scores_gemma":[0.99615955,0.002504161,0.0004729037,0.00024131594,0.00031436293,0.00030768785],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015345565,0.00012247944,0.00039358923,0.00030866123,0.0001689627,0.000042816413,0.000024262217,0.00008963261,0.00009146493],"category_scores_gemma":[0.015933225,0.00010758064,0.00009126271,0.00032033035,0.0000858929,0.00008224331,0.00011665501,0.0005291649,0.0000013738094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011289732,0.0004909577,0.8013258,0.00012184589,0.00020177523,0.0010162744,0.00034290404,0.000006986709,0.0000051788447,0.000021560232,0.0030045272,0.19233319],"study_design_scores_gemma":[0.0030326021,0.0028217274,0.9654746,0.00007366397,0.00014940005,0.0000056818644,0.0004869857,0.0011003758,0.000007686416,0.0023127068,0.02441393,0.00012065333],"about_ca_topic_score_codex":0.00011258684,"about_ca_topic_score_gemma":0.000018816687,"teacher_disagreement_score":0.19221254,"about_ca_system_score_codex":0.00032894756,"about_ca_system_score_gemma":0.00020776759,"threshold_uncertainty_score":0.992356},"labels":[],"label_agreement":null},{"id":"W4288969861","doi":"10.1016/j.jtocrr.2022.100385","title":"Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; EMD Serono; Otsuka America; Ribon Therapeutics; Takeda Oncology; Mirati Therapeutics; Bayer Fund; Abbott Laboratories; Clovis Oncology; National Center for Advancing Translational Sciences; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Ipsen Biopharmaceuticals; Novartis; Celgene; Unum Therapeutics; Merck KGaA; Servier; Gilead Sciences; Sanofi; Roche; Yuhan; Merck; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Canadian Asian Studies Association; AstraZeneca; Aerie Pharmaceuticals; Pfizer; Ariad Pharmaceuticals; Boehringer Ingelheim; Amgen; Regeneron Pharmaceuticals","keywords":"Crizotinib; Refractory (planetary science); Medicine; Phase (matter); Term (time); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lung cancer; Materials science; Chemistry; Physics","score_opus":0.20621207331927188,"score_gpt":0.5581480541043659,"score_spread":0.35193598078509397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288969861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917271,0.0021568073,0.0000041024623,0.0022768218,0.00017931112,0.0024400917,0.00013912187,0.0000069601565,0.0010696496],"genre_scores_gemma":[0.9971562,0.0015180458,0.000057035017,0.00006410634,0.000101865386,0.000103712926,0.000058804908,0.000011254124,0.0009289485],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99409014,0.0021658305,0.002229062,0.00044448004,0.0008377285,0.00023277513],"domain_scores_gemma":[0.9913029,0.007097328,0.0007051457,0.00040204596,0.0002622636,0.0002303133],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01945681,0.00012352515,0.0012088354,0.00013879893,0.00020492777,0.000014971188,0.00006236815,0.00008200975,0.00009991904],"category_scores_gemma":[0.01956892,0.000069549176,0.00019681324,0.00027363168,0.001172527,0.000049409166,0.0002268377,0.0006072416,1.4302691e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6334086,0.01242419,0.06969211,0.00050686806,0.0010299952,0.0018976808,0.0020819644,0.0000041014337,0.0024117767,0.00014553501,0.0022835138,0.27411368],"study_design_scores_gemma":[0.7848662,0.004274228,0.20165081,0.000578321,0.0006014607,0.00033200515,0.00025190553,0.00007210505,0.0006171382,0.0005328652,0.006085119,0.0001378177],"about_ca_topic_score_codex":0.0002939198,"about_ca_topic_score_gemma":0.000029506014,"teacher_disagreement_score":0.27397588,"about_ca_system_score_codex":0.000036810492,"about_ca_system_score_gemma":0.0006927697,"threshold_uncertainty_score":0.98868966},"labels":[],"label_agreement":null},{"id":"W4293565846","doi":"10.1016/j.jtocrr.2022.100400","title":"BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Alberta Health Services; McMaster University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"Genentech; Astellas Pharma; Regeneron Pharmaceuticals; Ipsen; BeiGene; Merck KGaA; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Adverse effect; Combination therapy; Internal medicine; Pharmacokinetics; Refractory (planetary science); Oncology; Confidence interval; Progression-free survival; Phases of clinical research; Clinical endpoint; Gastroenterology; Pharmacology; Chemotherapy; Immunotherapy; Cancer; Clinical trial","score_opus":0.07985497471285384,"score_gpt":0.466754628081248,"score_spread":0.38689965336839416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293565846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701494,0.00021095658,0.0000052816367,0.00057935563,0.00007714691,0.0017095007,0.00003372083,0.000012941497,0.00035613368],"genre_scores_gemma":[0.9975642,0.0003015524,0.000068278976,0.00006452186,0.000106872205,0.00025435482,0.0004478668,0.00003523862,0.0011570939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993967,0.0016719165,0.0012545098,0.0012449565,0.0012985253,0.0005631001],"domain_scores_gemma":[0.99820054,0.00027790543,0.00022077218,0.0007701899,0.00026243704,0.00026814902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008268111,0.00021020776,0.00043085936,0.000473719,0.0003516806,0.00008906345,0.00028714462,0.00021802433,0.00018023295],"category_scores_gemma":[0.0014544774,0.00017032766,0.00006432593,0.00072313484,0.00029939445,0.000028597067,0.0003846963,0.0013119698,0.0000028794266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024705272,0.02297845,0.9060702,0.000027284445,0.00007945799,0.009177971,0.0010869154,0.0002771115,0.023519661,0.000016222726,0.00055599294,0.011505477],"study_design_scores_gemma":[0.048384175,0.035229135,0.88170826,0.0001046962,0.000008059946,0.00010057016,0.0027542147,0.0019528095,0.0026933935,0.0008152293,0.025660567,0.00058888213],"about_ca_topic_score_codex":0.0062860805,"about_ca_topic_score_gemma":0.011761002,"teacher_disagreement_score":0.025104575,"about_ca_system_score_codex":0.00008825702,"about_ca_system_score_gemma":0.0006322899,"threshold_uncertainty_score":0.95027155},"labels":[],"label_agreement":null},{"id":"W4296202942","doi":"10.1016/j.jtocrr.2022.100408","title":"A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Medicine; Carboplatin; Tolerability; Pemetrexed; Rash; Internal medicine; Adverse effect; Neutropenia; Febrile neutropenia; Dosing; Loading dose; Oncology; Gastroenterology; Pharmacology; Urology; Toxicity; Chemotherapy; Cisplatin","score_opus":0.26697949158150086,"score_gpt":0.5310140040131872,"score_spread":0.26403451243168635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296202942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525666,0.00003736958,0.000008915657,0.00037560178,0.000028065557,0.003949753,0.000017538305,0.000010281609,0.00031580735],"genre_scores_gemma":[0.99853396,0.000013889199,0.00021840517,0.000023222246,0.000013403542,0.00065258774,0.000094680574,0.000015895705,0.00043393532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963043,0.0005466293,0.0010487875,0.00054580986,0.00128316,0.00027131013],"domain_scores_gemma":[0.9981243,0.00065448927,0.00027415468,0.00037285598,0.00034570848,0.00022848757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040145405,0.00013110794,0.0005318563,0.00019288916,0.00015193154,0.000027778085,0.00011815638,0.00004279125,0.00009530497],"category_scores_gemma":[0.0010063458,0.0000852965,0.00001843702,0.0012740531,0.00021619588,0.00009661741,0.00022187013,0.0009464382,4.917082e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045157306,0.12719405,0.7945217,0.0003926442,0.00016248932,0.0022874782,0.0011612717,0.00014447971,0.0003180114,0.00003867394,0.00019863136,0.028423265],"study_design_scores_gemma":[0.18265769,0.062395252,0.73933464,0.00033633228,0.0001937227,0.00006963471,0.0036857065,0.009379022,0.00025750266,0.00013978669,0.0011754795,0.00037521205],"about_ca_topic_score_codex":0.00025110535,"about_ca_topic_score_gemma":0.00019994267,"teacher_disagreement_score":0.13750038,"about_ca_system_score_codex":0.00016050457,"about_ca_system_score_gemma":0.0004689268,"threshold_uncertainty_score":0.41118556},"labels":[],"label_agreement":null},{"id":"W4296673382","doi":"10.1016/j.jtocrr.2022.100383","title":"Are We Underestimating Efficacy and Cost-Efficacy of Population Lung Cancer Computed Tomography Screening?","year":2022,"lang":"en","type":"editorial","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computed tomography; Lung cancer; Lung cancer screening; Medicine; Population; Radiology; Oncology; Environmental health","score_opus":0.14582471594950364,"score_gpt":0.5104202729002603,"score_spread":0.3645955569507566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296673382","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4254637,0.0612337,0.000052611438,0.011427503,0.48848686,0.011672466,0.00071679085,0.00028954959,0.00065683725],"genre_scores_gemma":[0.518779,0.025823388,0.00161033,0.000140185,0.4481658,0.0010756347,0.0029762182,0.00021671741,0.0012127557],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.994157,0.00043511274,0.0014394058,0.001059068,0.002450872,0.00045855404],"domain_scores_gemma":[0.9912737,0.0057218275,0.0010961236,0.000587591,0.0008421429,0.0004786413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034490677,0.0003000454,0.001236265,0.00035260996,0.00035771448,0.00007731158,0.000097548436,0.000567933,0.0001359959],"category_scores_gemma":[0.005810585,0.0002272786,0.00027148947,0.0005046762,0.00043497936,0.000055225704,0.00046303685,0.001988055,2.4375964e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045126633,0.0006778665,0.40623707,0.0010731465,0.00057085673,0.0008096569,0.000039438317,0.000031705044,4.2209106e-7,0.0000041577623,0.5677884,0.022316024],"study_design_scores_gemma":[0.0044356277,0.00090895244,0.61951625,0.0047101015,0.0006214381,0.000034695186,0.00004851219,0.00058665196,0.000003226963,0.00007912352,0.3688072,0.00024821854],"about_ca_topic_score_codex":0.0025346482,"about_ca_topic_score_gemma":0.00020140434,"teacher_disagreement_score":0.21327919,"about_ca_system_score_codex":0.00022464957,"about_ca_system_score_gemma":0.00051969336,"threshold_uncertainty_score":0.9268152},"labels":[],"label_agreement":null},{"id":"W4308522396","doi":"10.1016/j.jtocrr.2022.100431","title":"Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Merck Sharp and Dohme; EMD Serono; Astellas Pharma; Chugai Pharmaceutical; Seagen; Mirati Therapeutics; National Cancer Institute; Genomic Health; Genentech; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celgene; Pfizer","keywords":"Pembrolizumab; Medicine; Internal medicine; KRAS; Oncology; Hazard ratio; Chemotherapy; Confidence interval; Cancer; Immunotherapy; Colorectal cancer","score_opus":0.14070093782473087,"score_gpt":0.48564353220969525,"score_spread":0.3449425943849644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308522396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977655,0.00046092112,0.00015053485,0.007275486,0.00018534258,0.0016582432,0.00016337816,0.000025474652,0.0003040611],"genre_scores_gemma":[0.992723,0.0002677148,0.004355004,0.00056310464,0.00023784288,0.0003046508,0.00020466716,0.000044517412,0.0012995226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611413,0.00032800363,0.0011393807,0.0005532144,0.0014698486,0.00039543497],"domain_scores_gemma":[0.99483275,0.0034256738,0.00048978155,0.00027320674,0.0007144323,0.00026417326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046304544,0.00017715582,0.0007427492,0.00015504859,0.00036111436,0.0000381142,0.00007228113,0.000069503956,0.0002835081],"category_scores_gemma":[0.0010772011,0.000118663025,0.0001687686,0.0003332235,0.00094982464,0.00007742822,0.000053244137,0.00052959257,4.6268843e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15843213,0.002289125,0.69051373,0.00036189592,0.0068932283,0.0015777911,0.0019743622,0.000091220056,0.0002831131,0.0005465269,0.005527134,0.13150975],"study_design_scores_gemma":[0.043947194,0.011610263,0.9107717,0.000059557035,0.00021426588,0.00061770354,0.0012107306,0.00035621965,0.000083331586,0.00078618206,0.030086532,0.00025626886],"about_ca_topic_score_codex":0.00039202732,"about_ca_topic_score_gemma":0.000095253126,"teacher_disagreement_score":0.22025803,"about_ca_system_score_codex":0.00014715045,"about_ca_system_score_gemma":0.0019417242,"threshold_uncertainty_score":0.48389378},"labels":[],"label_agreement":null},{"id":"W4310859181","doi":"10.1016/j.jtocrr.2022.100444","title":"First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Ministère de la Santé et des Services sociaux; Merck","keywords":"Pembrolizumab; Medicine; Carboplatin; Internal medicine; Chemotherapy; Oncology; Confidence interval; Retrospective cohort study; Cancer; Immunotherapy; Cisplatin","score_opus":0.17584824350593595,"score_gpt":0.5244882499617058,"score_spread":0.34864000645576987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310859181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9285067,0.0019685652,0.000011418931,0.05861572,0.0010079839,0.0023880082,0.000023061519,0.0000886047,0.007389953],"genre_scores_gemma":[0.9397422,0.0060914247,0.00052297395,0.002447022,0.00049845024,0.00080402184,0.00005741763,0.000054188447,0.049782295],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99582106,0.000395826,0.0012343527,0.0008062474,0.0011213905,0.00062112295],"domain_scores_gemma":[0.9938453,0.003994919,0.0007705407,0.00065396057,0.00039831165,0.00033696738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007913405,0.0002011496,0.0008178765,0.0002202562,0.00086027704,0.000032241678,0.00014682187,0.00016155036,0.00083509344],"category_scores_gemma":[0.0035750263,0.00014624921,0.00038243417,0.00041558495,0.00058028946,0.00008823513,0.00032711294,0.00090982154,0.0000041717535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16085342,0.0039712633,0.3868617,0.00064015953,0.0010737629,0.0047789337,0.00080252904,0.000041118616,0.0018896457,0.000164007,0.09791201,0.34101146],"study_design_scores_gemma":[0.012915039,0.0058136918,0.0985128,0.000034514625,0.00005713428,0.00062365667,0.00020917438,0.00017887849,0.00016418961,0.0005407605,0.88076335,0.00018682948],"about_ca_topic_score_codex":0.00095796277,"about_ca_topic_score_gemma":0.0019097571,"teacher_disagreement_score":0.78285134,"about_ca_system_score_codex":0.00074851175,"about_ca_system_score_gemma":0.0011369738,"threshold_uncertainty_score":0.91436875},"labels":[],"label_agreement":null},{"id":"W4313856340","doi":"10.1016/j.jtocrr.2022.100460","title":"Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Systemic therapy; Targeted therapy; Medicine; Oncology; Immune checkpoint; Mutation; Immune system; Cancer research; Internal medicine; Immunotherapy; Immunology; Biology; Cancer; Genetics; Gene","score_opus":0.050758505383652536,"score_gpt":0.391417087290026,"score_spread":0.34065858190637344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313856340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983583,0.00068003836,0.000011518357,0.00007341822,0.000084689615,0.0006314796,0.000019301395,0.000009241761,0.00013198503],"genre_scores_gemma":[0.9970278,0.0025153786,0.000017332108,0.000006416979,0.00007613729,0.00009588905,0.00012846218,0.000013355232,0.000119238735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789876,0.00067083695,0.0005384329,0.00045650333,0.00021234878,0.0002231192],"domain_scores_gemma":[0.99892926,0.0004410563,0.00011555484,0.00022570614,0.00016917137,0.00011922256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003255425,0.00012006076,0.00031730114,0.00013641118,0.00006666778,0.000019308232,0.000034164237,0.00014425456,0.0000024285523],"category_scores_gemma":[0.00035229517,0.00008703609,0.00006767119,0.0001779392,0.0002310046,0.000004359153,0.00008584491,0.00013255235,5.6922795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076562504,0.00022136081,0.60078615,0.00025923137,0.00008045183,0.0006922451,0.000089103996,0.0000057918346,0.38806018,0.000021533193,0.000015747335,0.009002562],"study_design_scores_gemma":[0.0013392394,0.0017625284,0.74081224,0.00023496091,0.000005174799,0.00004187636,0.00006639505,0.000056852026,0.2553997,0.00014428193,0.000053120413,0.00008364192],"about_ca_topic_score_codex":0.0013654385,"about_ca_topic_score_gemma":0.0002756971,"teacher_disagreement_score":0.14002606,"about_ca_system_score_codex":0.000018216559,"about_ca_system_score_gemma":0.00015901777,"threshold_uncertainty_score":0.35492286},"labels":[],"label_agreement":null},{"id":"W4318954097","doi":"10.1016/j.jtocrr.2023.100469","title":"Interventions Designed to Increase the Uptake of Lung Cancer Screening: An Equity-Oriented Scoping Review","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canadian Partnership Against Cancer; Public Health Ontario; University of Toronto; Women's College Hospital; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Partenariat Canadien Contre Le Cancer; Women's College Hospital","keywords":"Psychological intervention; Grey literature; Scopus; MEDLINE; Medicine; Health equity; Family medicine; Health care; Gerontology; Nursing; Public health; Political science","score_opus":0.3764621298431538,"score_gpt":0.6200331712581714,"score_spread":0.24357104141501756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318954097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92006916,0.044367895,0.00008681509,0.029025221,0.00034319088,0.004782221,0.000017633154,0.00008730505,0.0012205786],"genre_scores_gemma":[0.9018828,0.092160456,0.0005410683,0.0014393233,0.0004135802,0.0013707225,0.000052449173,0.00003388504,0.0021057015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969011,0.00037467125,0.0010916959,0.00043444103,0.0008613748,0.0003367193],"domain_scores_gemma":[0.9975387,0.0006330183,0.00016407575,0.00057062303,0.00060842634,0.00048518804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010648861,0.00009967339,0.00046955887,0.00011485879,0.00019621295,0.000024795081,0.00008741911,0.00006258648,0.00018804643],"category_scores_gemma":[0.0048053353,0.000056197943,0.00024042808,0.00075909874,0.00022414552,0.00005546753,0.00038210352,0.00029294632,0.000005368704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000650752,0.0019061456,0.52409035,0.03184663,0.0007312002,0.0025371346,0.00026357346,0.0000085193615,0.000107438136,0.0003011453,0.098067775,0.33948937],"study_design_scores_gemma":[0.0023250603,0.0031167245,0.6743927,0.30213812,0.0008951317,0.00012965826,0.00018439427,0.000183333,0.00028106815,0.0002974581,0.01581214,0.00024420116],"about_ca_topic_score_codex":0.0009818088,"about_ca_topic_score_gemma":0.00043672326,"teacher_disagreement_score":0.33924517,"about_ca_system_score_codex":0.000061718296,"about_ca_system_score_gemma":0.0005053586,"threshold_uncertainty_score":0.5752782},"labels":[],"label_agreement":null},{"id":"W4321793664","doi":"10.1016/j.jtocrr.2023.100482","title":"Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Performance status; Pembrolizumab; Internal medicine; Nivolumab; Emergency department; Oncology; Immunotherapy; Cancer; Nursing","score_opus":0.10305086351462374,"score_gpt":0.46670079103210477,"score_spread":0.36364992751748104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321793664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838865,0.00034823894,3.099327e-7,0.00026809057,0.00004560785,0.0007516809,0.00000820539,0.00002117561,0.00016801737],"genre_scores_gemma":[0.9978762,0.0018535003,0.000016781876,0.000015701165,0.000015339385,0.000016443128,0.00008757498,0.000016221502,0.00010221897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782836,0.000122593,0.0007000918,0.00032204142,0.0006792292,0.00034769217],"domain_scores_gemma":[0.99890727,0.0001375008,0.00019564437,0.000244478,0.00033654977,0.00017855626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018009522,0.00012252112,0.00047202597,0.00021929576,0.00007900366,0.000011264747,0.00002174059,0.00007339064,0.000008248023],"category_scores_gemma":[0.00022229031,0.000064119486,0.00006293181,0.000619415,0.0003169252,0.0000643398,0.000034509852,0.0002933677,3.931385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009633495,0.0002513454,0.90500104,0.0001438946,0.00007807264,0.0000449945,0.00024656762,0.0000050278863,0.000026318367,4.0915134e-7,0.000023857026,0.08454498],"study_design_scores_gemma":[0.0058168056,0.01227145,0.98071384,0.00054904143,0.0000066085013,0.0000040247696,0.000277713,0.000016906133,0.00013229436,0.0000014090276,0.00013618387,0.00007372022],"about_ca_topic_score_codex":0.0010602609,"about_ca_topic_score_gemma":0.00017968215,"teacher_disagreement_score":0.084471256,"about_ca_system_score_codex":0.00013553762,"about_ca_system_score_gemma":0.00048160017,"threshold_uncertainty_score":0.2614717},"labels":[],"label_agreement":null},{"id":"W4362678254","doi":"10.1016/j.jtocrr.2023.100515","title":"Meta-Analysis of Rates and Risk Factors for Local Recurrence in Surgically Resected Patients With NSCLC and Differences Between Asian and Non-Asian Populations","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medtronic; Sapheon","keywords":"Medicine; Lymphovascular invasion; Internal medicine; Relative risk; Population; Oncology; Meta-analysis; Confidence interval; Surgery; Cancer; Metastasis","score_opus":0.2965848705078426,"score_gpt":0.4896689564576886,"score_spread":0.193084085949846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362678254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976524,0.00038429585,0.000014383022,0.0010251702,0.000017272074,0.0007549662,0.00009240264,0.0000083705145,0.000050730523],"genre_scores_gemma":[0.9982945,0.0012852668,0.000112524074,0.0000041656576,0.000017360691,0.00008477589,0.00012992941,0.000007821717,0.0000636915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977812,0.00023465273,0.0006859664,0.0005336814,0.0005168085,0.00024767776],"domain_scores_gemma":[0.9970994,0.0019131176,0.00018386499,0.00020952086,0.0002940601,0.0003000294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019452599,0.0001293556,0.0010236172,0.00033842676,0.0001321503,0.00003658055,0.000027957332,0.000112793285,0.00001212278],"category_scores_gemma":[0.0010576497,0.00006810476,0.0001402147,0.0006949773,0.0005504688,0.000054740573,0.00008423011,0.00024882032,1.0129734e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015537643,0.0001888897,0.98568285,0.0000799774,0.0069784163,0.00004573338,0.00019481091,7.338185e-7,1.9746408e-7,0.000008920066,0.000044857556,0.006619232],"study_design_scores_gemma":[0.0010099717,0.0012306052,0.98593044,0.000056922334,0.010902182,0.000001205813,0.00017536657,0.0001770254,0.000005617485,0.00040144066,0.000036203535,0.000073028306],"about_ca_topic_score_codex":0.0012916827,"about_ca_topic_score_gemma":0.0022999037,"teacher_disagreement_score":0.0065462035,"about_ca_system_score_codex":0.000017991315,"about_ca_system_score_gemma":0.000081504026,"threshold_uncertainty_score":0.27772316},"labels":[],"label_agreement":null},{"id":"W4377982006","doi":"10.1016/j.jtocrr.2023.100530","title":"Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Québec Science (Canada); McGill University Health Centre","funders":"","keywords":"ROS1; Immunohistochemistry; Adenocarcinoma; Lung cancer; Carcinogenesis; Cancer research; Fluorescence in situ hybridization; Medicine; Biology; Internal medicine; Pathology; Cancer; Oncology; Gene; Genetics","score_opus":0.04095527057484923,"score_gpt":0.4228655320139387,"score_spread":0.3819102614390895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377982006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957019,0.0010769046,0.000008530085,0.0015353916,0.00004367091,0.000919448,0.000038166778,0.00013091946,0.0005450641],"genre_scores_gemma":[0.9960636,0.0002975045,0.00011711283,0.000057521924,0.00003417904,0.00018286331,0.0005131736,0.000040907882,0.00269316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662906,0.00031429523,0.0010599312,0.0007312681,0.0007985004,0.00046697079],"domain_scores_gemma":[0.9973853,0.00097073097,0.0002884931,0.00037854505,0.00052243506,0.00045445096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002318807,0.00020248063,0.00054579537,0.00016786656,0.0002919627,0.0000536853,0.00005757635,0.00032152823,0.00003117998],"category_scores_gemma":[0.002874308,0.00013144639,0.00007140737,0.0008882518,0.00064466853,0.00009916628,0.000059335223,0.0009726389,0.0000020752386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00111454,0.0006206935,0.9838305,0.00010554296,0.000259921,0.0039008558,0.00037333407,0.000004069862,0.0074632107,0.0000013882172,0.0018087139,0.0005172251],"study_design_scores_gemma":[0.0065898728,0.0011660329,0.9886419,0.0011886794,0.00021767679,0.00022743134,0.00052300195,0.00034117652,0.0007059748,0.000080500286,0.00013736542,0.00018035146],"about_ca_topic_score_codex":0.0003609606,"about_ca_topic_score_gemma":0.00010441283,"teacher_disagreement_score":0.006757236,"about_ca_system_score_codex":0.00015437626,"about_ca_system_score_gemma":0.0005762222,"threshold_uncertainty_score":0.53602284},"labels":[],"label_agreement":null},{"id":"W4385973055","doi":"10.1016/j.jtocrr.2023.100562","title":"Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Kingston Health Sciences Centre; William Osler Health System; Queen's University; Brampton Civic Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; EMD Serono; Genentech; Incyte; Canadian Cancer Society Research Institute; Helsinn; BeiGene; Merck KGaA; Princess Margaret Cancer Foundation; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Oncology; Toxicity; Targeted therapy; Cancer","score_opus":0.09678955994710657,"score_gpt":0.45914478222649396,"score_spread":0.3623552222793874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385973055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941149,0.001465659,0.0000073612377,0.0017608805,0.00005431168,0.0021985879,0.000004535681,0.000077492456,0.00031626807],"genre_scores_gemma":[0.9966195,0.00074939884,0.0011872285,0.000055747576,0.00011274469,0.00040953397,0.000048810438,0.000024039211,0.00079298014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975727,0.00031719077,0.0005584336,0.0005482719,0.00061858987,0.0003848187],"domain_scores_gemma":[0.99867415,0.00047994353,0.0001204913,0.00021021717,0.0002456553,0.0002695162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024626807,0.00015774713,0.00038098768,0.00026475533,0.00023681679,0.00011486455,0.000031596337,0.00013484176,0.000023688859],"category_scores_gemma":[0.00083687506,0.00009938568,0.00004831971,0.0005410954,0.00055710407,0.00012465066,0.00008249783,0.00042614073,0.0000021642409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024310453,0.0024604443,0.7601094,0.0006503581,0.0012625495,0.008664532,0.012509972,0.0000077825,0.020103117,0.00028675082,0.0003678222,0.19114622],"study_design_scores_gemma":[0.011774656,0.007954359,0.9517355,0.0010293472,0.00026932047,0.00037832715,0.0054108566,0.00011680278,0.007766501,0.0060724393,0.0070429514,0.00044891797],"about_ca_topic_score_codex":0.00060635176,"about_ca_topic_score_gemma":0.00011879655,"teacher_disagreement_score":0.19162613,"about_ca_system_score_codex":0.000042832526,"about_ca_system_score_gemma":0.00037371946,"threshold_uncertainty_score":0.40528303},"labels":[],"label_agreement":null},{"id":"W4386570892","doi":"10.1016/j.jtocrr.2023.100572","title":"Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Daiichi Sankyo Europe; National Cancer Institute; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Oryzon Genomics; BeiGene; Merck KGaA; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Quality of life (healthcare); Hazard ratio; Confidence interval; Etoposide; Oncology; Chemotherapy; Surgery; Cancer; Pathology; Immunotherapy; Nursing","score_opus":0.3304689780494397,"score_gpt":0.5523388797000741,"score_spread":0.22186990165063442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386570892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96941686,0.0015630077,0.000007510103,0.023386361,0.0001789534,0.004967786,0.000039853607,0.000081436185,0.00035825532],"genre_scores_gemma":[0.98804915,0.0061097336,0.00019432054,0.00072592404,0.0001380365,0.0005180137,0.000047912967,0.00004573489,0.004171183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923856,0.0007601757,0.0031143716,0.0010265338,0.0017589967,0.00095430866],"domain_scores_gemma":[0.98994005,0.0061202226,0.00059859024,0.0007271388,0.0015467546,0.0010672393],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014696706,0.0002480171,0.0014860311,0.00042279952,0.00029966075,0.000035676527,0.0000917074,0.0002589514,0.00008831003],"category_scores_gemma":[0.06873883,0.00016514855,0.00017466162,0.0011662035,0.0007503187,0.00008073738,0.00044729243,0.0009255249,0.00000687068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12533867,0.0019458133,0.71250457,0.0037454031,0.0012191229,0.006545985,0.0053763855,0.00006545038,0.0011147034,0.0001061823,0.057223015,0.08481473],"study_design_scores_gemma":[0.01976062,0.014483881,0.94160795,0.0011443476,0.000023073933,0.00016408622,0.0015371551,0.00054792577,0.0004693606,0.0018788484,0.018022748,0.00035999357],"about_ca_topic_score_codex":0.0045666182,"about_ca_topic_score_gemma":0.0014598215,"teacher_disagreement_score":0.22910342,"about_ca_system_score_codex":0.00013432807,"about_ca_system_score_gemma":0.001973254,"threshold_uncertainty_score":0.9391056},"labels":[],"label_agreement":null},{"id":"W4386954645","doi":"10.1016/j.jtocrr.2023.100580","title":"Does Multidisciplinary Team Management Improve Clinical Outcomes in NSCLC? A Systematic Review With Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"JTO Clinical and Research Reports","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Meta-analysis; Hazard ratio; Confidence interval; Internal medicine; Grading (engineering); Random effects model; Data extraction; MEDLINE","score_opus":0.5955770920631436,"score_gpt":0.6212303727667053,"score_spread":0.025653280703561765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386954645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023150857,0.9883131,0.0000066781367,0.0009154004,0.00022500734,0.009538785,0.000022954908,0.000072913535,0.0008820363],"genre_scores_gemma":[0.000058879432,0.98121715,0.00036811962,0.00024670176,0.00017258947,0.0025903638,0.00006369354,0.00006839544,0.015214099],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9827664,0.003100309,0.007935785,0.0020976127,0.0032246693,0.0008752059],"domain_scores_gemma":[0.9893202,0.005130902,0.0017542117,0.0024624872,0.0005361776,0.00079601404],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.051246766,0.0006757879,0.017986659,0.00085488823,0.00015796314,0.000099023775,0.0004012951,0.00061841053,0.000069987924],"category_scores_gemma":[0.009153129,0.0002505796,0.0068465015,0.0028292423,0.0006521788,0.000102438506,0.0010197209,0.002807192,0.00007539426],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058419344,0.00040775488,0.009622187,0.80055803,0.15225117,0.01800526,0.000010156483,9.800429e-8,9.475462e-10,0.0000104716755,0.0013552553,0.017721223],"study_design_scores_gemma":[0.00042673506,0.0007835571,0.002014744,0.33321917,0.6148686,0.00026632388,0.00014295123,0.000007684415,6.7453505e-9,0.00011920089,0.04768404,0.0004670265],"about_ca_topic_score_codex":0.00028401313,"about_ca_topic_score_gemma":0.00038857217,"teacher_disagreement_score":0.46733883,"about_ca_system_score_codex":0.00016093459,"about_ca_system_score_gemma":0.0007605069,"threshold_uncertainty_score":0.99999464},"labels":[],"label_agreement":null},{"id":"W4387783616","doi":"10.1016/j.jtocrr.2023.100594","title":"Health Care Utilization and Costs in Lung Cancer Screening Participants—A Propensity-Matched Economic Analysis","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Alberta Health; Simon Fraser University; University of Alberta; University of Saskatchewan; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Medicine; Lung cancer; Cohort; Confidence interval; Propensity score matching; Cohort study; Health care; Cancer; Demography; Emergency medicine; Internal medicine","score_opus":0.3476252898537681,"score_gpt":0.4919756895256912,"score_spread":0.1443503996719231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387783616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836351,0.010114359,0.00007579954,0.0039080763,0.00024828553,0.00047581276,0.00006303099,0.00003314873,0.0014463505],"genre_scores_gemma":[0.98338765,0.0155917825,0.0000586789,0.0002258783,0.00015632094,0.00006839601,0.00003254406,0.000018595038,0.00046017562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969783,0.00010677444,0.001421363,0.00075403193,0.00008153653,0.0006579972],"domain_scores_gemma":[0.9986284,0.00022401028,0.00040165198,0.000308593,0.000089086716,0.0003483016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070374114,0.00012946964,0.0009104388,0.00060719665,0.00022218758,0.00013926534,0.00008661456,0.00015826825,0.00008335176],"category_scores_gemma":[0.00084556284,0.00013127664,0.00010794871,0.0006899223,0.0002481082,0.00026639143,0.0002017528,0.000377143,0.00002510292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038356895,0.000022289983,0.9690903,0.000059417103,0.00012309059,0.000043030876,0.00048001512,0.00022354543,2.7720552e-7,0.0012177889,0.0016216986,0.027080178],"study_design_scores_gemma":[0.0003973087,0.00007601382,0.97227174,0.000056280744,0.000015193343,0.0000022975983,0.000248402,0.01233078,0.000003049878,0.001161952,0.013270666,0.00016634053],"about_ca_topic_score_codex":0.010419363,"about_ca_topic_score_gemma":0.009650995,"teacher_disagreement_score":0.026913838,"about_ca_system_score_codex":0.00029096098,"about_ca_system_score_gemma":0.00025744212,"threshold_uncertainty_score":0.99617034},"labels":[],"label_agreement":null},{"id":"W4388666126","doi":"10.1016/j.jtocrr.2023.100601","title":"Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Internal medicine; Cohort; Oncology; PD-L1; Immunotherapy; Clinical endpoint; Chemotherapy; Population; Cancer; Clinical trial","score_opus":0.20496001696559404,"score_gpt":0.47969571614272694,"score_spread":0.2747356991771329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388666126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460703,0.00016032711,0.000039543225,0.0019373065,0.00015159583,0.0029038403,0.0000113296965,0.00008659408,0.00010241624],"genre_scores_gemma":[0.9923015,0.0012559654,0.0003410174,0.00032641986,0.00016195455,0.0005128831,0.000016400409,0.00006525266,0.005018603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581206,0.0005301851,0.0008680453,0.0010834038,0.00083424797,0.00087205844],"domain_scores_gemma":[0.996982,0.0014240467,0.00010882459,0.0005701805,0.00028126675,0.00063373137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005896901,0.0003245481,0.00084616017,0.0005367524,0.00020191442,0.00020635557,0.00009294976,0.00020958393,0.00003713235],"category_scores_gemma":[0.0008550206,0.00017342721,0.000091685586,0.0011526039,0.00051150564,0.00018508913,0.0002223721,0.00053865643,0.000005366856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10213824,0.00021664912,0.815416,0.0002233197,0.00024015966,0.004934121,0.0007157847,7.0145444e-7,0.0045088343,0.000009335141,0.00028642503,0.07131042],"study_design_scores_gemma":[0.0066578537,0.0083187325,0.96982396,0.0011496763,0.000030257552,0.00041618987,0.00022487005,0.0000097938755,0.0023762367,0.000116292715,0.010567018,0.0003091088],"about_ca_topic_score_codex":0.00234504,"about_ca_topic_score_gemma":0.0042738663,"teacher_disagreement_score":0.15440796,"about_ca_system_score_codex":0.000095773226,"about_ca_system_score_gemma":0.0003486816,"threshold_uncertainty_score":0.7072156},"labels":[],"label_agreement":null},{"id":"W4388798703","doi":"10.1016/j.jtocrr.2023.100602","title":"Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval; Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec; Université du Québec à Trois-Rivières","funders":"Fonds de Recherche du Québec - Santé; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval","keywords":"Pembrolizumab; Nivolumab; Radiomics; Concordance; Medicine; Oncology; Internal medicine; Cohort; Imaging biomarker; Biomarker; Radiology; Immunotherapy; Cancer; Magnetic resonance imaging","score_opus":0.07396518050724483,"score_gpt":0.44678724647584117,"score_spread":0.37282206596859635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388798703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947504,0.00034337986,0.000060288556,0.0029773698,0.00009846879,0.0014546455,0.0000036773606,0.00012580943,0.00018599075],"genre_scores_gemma":[0.9984725,0.00017116335,0.00067108794,0.00007490708,0.000058348593,0.0001283142,0.000030630858,0.000029275767,0.00036377553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644244,0.00037813996,0.00074844697,0.00083614513,0.0010216442,0.000573213],"domain_scores_gemma":[0.99779177,0.0009424226,0.000112264504,0.0003035784,0.00025090808,0.00059907226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005958839,0.00022715388,0.0006995673,0.00040190516,0.0002726597,0.00009761551,0.00006127124,0.000103022074,0.0000047177377],"category_scores_gemma":[0.0051229787,0.00013879039,0.000066288754,0.0005570812,0.0012931199,0.000095423595,0.0001529236,0.000908062,0.0000011736837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012005654,0.0008614472,0.9495331,0.000103619015,0.00013957029,0.0086069,0.00009208655,0.000008917201,0.00006287565,0.0000056274525,0.000072909635,0.03931235],"study_design_scores_gemma":[0.013014603,0.00111612,0.9590725,0.00026327113,0.000060346607,0.00033335856,0.0003691392,0.02494339,0.000008050064,0.000038306753,0.0006271721,0.00015377965],"about_ca_topic_score_codex":0.0008931589,"about_ca_topic_score_gemma":0.00021378884,"teacher_disagreement_score":0.03915857,"about_ca_system_score_codex":0.000040439463,"about_ca_system_score_gemma":0.00042194838,"threshold_uncertainty_score":0.6133054},"labels":[],"label_agreement":null},{"id":"W4389101382","doi":"10.1016/j.jtocrr.2023.100615","title":"The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Mount Sinai Hospital; William Osler Health System; Lakeridge Health; Princess Margaret Cancer Centre","funders":"Array BioPharma; GlaxoSmithKline; AstraZeneca; Open Society Institute; Princess Margaret Cancer Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Interquartile range; Medicine; Context (archaeology); Biopsy; Liquid biopsy; Willingness to pay; Lung cancer; Internal medicine; Oncology; Cancer","score_opus":0.08530398357245508,"score_gpt":0.3921635944410951,"score_spread":0.30685961086864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389101382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980705,0.000062172534,0.0000039076026,0.00048560713,0.0003081575,0.0006292615,0.00008477162,0.000008760565,0.00034689758],"genre_scores_gemma":[0.9991223,0.00009189758,0.00016053606,0.000042571897,0.00027506214,0.000037282927,0.00013354604,0.000020986685,0.0001157794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674606,0.00026496354,0.0013891316,0.00065454957,0.00057421,0.00037109948],"domain_scores_gemma":[0.99639374,0.0010300766,0.00044421334,0.00076894974,0.001026105,0.0003369319],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047341078,0.000119912824,0.0002771726,0.00009212763,0.00028694715,0.00004839501,0.00015178339,0.0001204243,0.0000018467587],"category_scores_gemma":[0.03202991,0.00008468868,0.000083962295,0.0004573215,0.00024906165,0.000003969365,0.00031376322,0.00022977934,0.0000013266915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014375056,0.00068669184,0.83124685,0.000064110805,0.00032153723,0.0046788002,0.0017566821,0.0010458768,0.14233221,0.00002411531,0.004361896,0.012043741],"study_design_scores_gemma":[0.0008727465,0.0032677713,0.9762534,0.00013330908,0.000038912578,0.00017305353,0.0012623711,0.00043911696,0.007715087,0.00045257708,0.009162257,0.000229426],"about_ca_topic_score_codex":0.078265056,"about_ca_topic_score_gemma":0.011590194,"teacher_disagreement_score":0.14500654,"about_ca_system_score_codex":0.000027173968,"about_ca_system_score_gemma":0.0011240105,"threshold_uncertainty_score":0.9761237},"labels":[],"label_agreement":null},{"id":"W4389839591","doi":"10.1016/j.jtocrr.2023.100623","title":"Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; National Institutes of Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Damon Runyon Cancer Research Foundation; LUNGevity Foundation; Computer Modelling Group; Amgen; Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; V Foundation for Cancer Research","keywords":"Profiling (computer programming); Mutant; Transformation (genetics); Cancer research; Oncology; Computational biology; Medicine; Biology; Computer science; Gene; Genetics","score_opus":0.1404393992648889,"score_gpt":0.44822864770405335,"score_spread":0.30778924843916444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389839591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039716,0.0024104936,0.000145153,0.0020939736,0.00050042255,0.001887195,0.000036138845,0.000110783345,0.0024186864],"genre_scores_gemma":[0.9928075,0.005084452,0.0004076535,0.00013676028,0.00047875982,0.00008768442,0.00022297,0.000037546022,0.0007366739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99406177,0.00032230868,0.002370684,0.0007163702,0.0017688605,0.0007600188],"domain_scores_gemma":[0.99567443,0.0011972747,0.00046554935,0.0007058134,0.001502558,0.00045440227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066237017,0.00022463546,0.0008926088,0.0003237271,0.00027043032,0.000053214073,0.00014328954,0.00028280343,0.000062985935],"category_scores_gemma":[0.001966058,0.00015607725,0.00034906753,0.0005948001,0.0009856006,0.00014513246,0.00033169912,0.0012173973,0.000033615237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008994841,0.0022807096,0.50596106,0.0049742176,0.003070487,0.04556911,0.005856164,0.00013570131,0.198232,0.00018140856,0.007191608,0.21755272],"study_design_scores_gemma":[0.010053993,0.0049876226,0.8477963,0.0010945437,0.00050307333,0.0015670501,0.0056945905,0.00440617,0.06526286,0.010165238,0.04761342,0.00085508934],"about_ca_topic_score_codex":0.0005057165,"about_ca_topic_score_gemma":0.000034568737,"teacher_disagreement_score":0.3418353,"about_ca_system_score_codex":0.000093429364,"about_ca_system_score_gemma":0.0010387237,"threshold_uncertainty_score":0.6364646},"labels":[],"label_agreement":null},{"id":"W4389850548","doi":"10.1016/j.jtocrr.2023.100621","title":"Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Oncology; Adjuvant; Internal medicine; Subgroup analysis; Stage (stratigraphy); Epidermal growth factor receptor; Meta-analysis; Biology; Cancer; Erlotinib","score_opus":0.04608447736501201,"score_gpt":0.43569447291931473,"score_spread":0.3896099955543027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389850548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955035,0.00008659102,0.00003240484,0.0019214867,0.000116804826,0.0012805817,0.00007287435,0.00004477749,0.0009410064],"genre_scores_gemma":[0.9960591,0.000027658494,0.00016712896,0.00020011539,0.00010674291,0.00028798045,0.0002854227,0.000022640397,0.002843174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996648,0.00024821976,0.0008063248,0.00069679786,0.0011370662,0.00046358234],"domain_scores_gemma":[0.9979722,0.00037355337,0.00013172012,0.0004106664,0.0006495258,0.00046235643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017818299,0.00015771593,0.00051975955,0.00065258273,0.00020649316,0.000058913833,0.000048626844,0.00007575775,0.00017235577],"category_scores_gemma":[0.0007983295,0.00010333519,0.00013600376,0.0024697082,0.00022269171,0.00009589425,0.00011556666,0.00044782084,0.000040608127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023054625,0.0004662641,0.9870516,0.00004641959,0.0006481824,0.0046641645,0.00056851964,0.000051145413,0.0000065657196,0.000009371164,0.0006934108,0.0034889157],"study_design_scores_gemma":[0.002287881,0.0021713949,0.9928375,0.00017423341,0.0002835419,0.000016810802,0.0002115733,0.00019834125,0.000015203267,0.00008259268,0.0015947105,0.00012623175],"about_ca_topic_score_codex":0.0012753629,"about_ca_topic_score_gemma":0.0012840749,"teacher_disagreement_score":0.0057859067,"about_ca_system_score_codex":0.00014860318,"about_ca_system_score_gemma":0.00028214575,"threshold_uncertainty_score":0.42138866},"labels":[],"label_agreement":null},{"id":"W4391065397","doi":"10.1016/j.jtocrr.2024.100633","title":"A Prospective Observational Study of Physical Activity Levels and Physical Fitness of People at High Risk for Lung Cancer","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; Medical Research Council; Royal Melbourne Hospital; University of Melbourne; Institut National de la Santé et de la Recherche Médicale; AstraZeneca; Bristol-Myers Squibb","keywords":"Observational study; Lung cancer; Physical activity; Medicine; Physical fitness; Cancer; Prospective cohort study; Physical therapy; Oncology; Gerontology; Environmental health; Internal medicine","score_opus":0.2351276828401595,"score_gpt":0.5323852277702925,"score_spread":0.297257544930133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391065397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974174,0.00034665066,0.00001853749,0.0005193881,0.00020853679,0.0013107852,0.00010758196,0.000015359761,0.000055784443],"genre_scores_gemma":[0.9983051,0.000075433854,0.000012284969,0.000005605795,0.0005698275,0.00030145628,0.000005113763,0.000015089849,0.00071013527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979353,0.00016812234,0.00034430585,0.00051556976,0.00083804724,0.00019863358],"domain_scores_gemma":[0.9968681,0.0019491699,0.0001158001,0.00022710428,0.00068766053,0.00015216276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016550762,0.000105360785,0.0005760265,0.0000617784,0.000098006865,0.000016109763,0.00003525168,0.000076013115,0.000015796473],"category_scores_gemma":[0.0010416526,0.00007125196,0.00014597499,0.00030209572,0.0003349916,0.000071967144,0.00017365703,0.0004350743,1.3911291e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010141493,0.0017207586,0.9789884,0.0010199073,0.00031290427,0.00006701509,0.004411269,0.000003987037,0.0006291439,0.00017238154,0.00042267577,0.011237407],"study_design_scores_gemma":[0.000965857,0.001824408,0.9902397,0.0001958518,0.00018520308,0.000011037296,0.00046527243,0.0035618776,0.0010236489,0.0012856009,0.0001656591,0.00007587628],"about_ca_topic_score_codex":0.0037761764,"about_ca_topic_score_gemma":0.0021630821,"teacher_disagreement_score":0.011251306,"about_ca_system_score_codex":0.00007311225,"about_ca_system_score_gemma":0.00037979594,"threshold_uncertainty_score":0.57084745},"labels":[],"label_agreement":null},{"id":"W4391792531","doi":"10.1016/j.jtocrr.2024.100645","title":"Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; National Institutes of Health; Array BioPharma; Massachusetts General Hospital; Lunit; Amgen; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Alectinib; Medicine; Oncology; Crizotinib; Internal medicine; Lung cancer","score_opus":0.03893543307576351,"score_gpt":0.42166519799897556,"score_spread":0.38272976492321203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391792531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444896,0.0010216227,0.000008695916,0.0006354416,0.00016217446,0.0016503287,0.00004821874,0.000037053243,0.0019875222],"genre_scores_gemma":[0.998805,0.00035620955,0.00015664303,0.0000279463,0.00004945421,0.000033127148,0.000048016078,0.000025766403,0.0004978256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715024,0.00031887856,0.000800539,0.000607092,0.0007517738,0.00037147175],"domain_scores_gemma":[0.99777806,0.0011658006,0.00011376121,0.00023186716,0.00033491527,0.0003756046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014202519,0.000168826,0.00055428233,0.00021293851,0.00013298943,0.000056014134,0.000025305859,0.00010323941,0.000012170538],"category_scores_gemma":[0.0007619037,0.000101875776,0.000056644716,0.00043516664,0.0004206764,0.00008160734,0.00005894373,0.00059633626,0.0000010878483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026517546,0.0022830702,0.78638905,0.0016823433,0.0018653597,0.009260092,0.0025696568,0.000016625912,0.00004304105,0.0004312682,0.0010254367,0.16791649],"study_design_scores_gemma":[0.008083154,0.005798052,0.98152375,0.0025148487,0.00030332373,0.00022717007,0.00026440798,0.00010570863,0.000042394313,0.000069182905,0.00095309614,0.000114918075],"about_ca_topic_score_codex":0.00026985834,"about_ca_topic_score_gemma":0.00006324433,"teacher_disagreement_score":0.19513467,"about_ca_system_score_codex":0.00015600592,"about_ca_system_score_gemma":0.00048591368,"threshold_uncertainty_score":0.41543734},"labels":[],"label_agreement":null},{"id":"W4391919142","doi":"10.1016/j.jtocrr.2024.100647","title":"Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cabozantinib; Medicine; Exon; Exon skipping; Mutation; Cancer research; Oncology; Targeted therapy; Internal medicine; Cancer; Genetics; Gene; Biology","score_opus":0.06866051547325637,"score_gpt":0.4670181337328081,"score_spread":0.39835761825955174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391919142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303937,0.0022227645,0.000020043854,0.0018476583,0.00022411169,0.00081028166,0.0000070872557,0.000051130304,0.0017775457],"genre_scores_gemma":[0.9973616,0.0002747717,0.00073063624,0.00008503124,0.00013472942,0.00012175324,0.000023199553,0.000023870412,0.0012444169],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997204,0.0003173308,0.0008472868,0.000696664,0.0006291589,0.00030554182],"domain_scores_gemma":[0.9981371,0.0008742958,0.00011050032,0.00032566697,0.00024021896,0.0003122059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00520333,0.00013033315,0.0003350651,0.00030984575,0.00016049873,0.000110993395,0.000016993976,0.00012368667,0.000043346263],"category_scores_gemma":[0.0018063604,0.00008720956,0.000058311107,0.000443949,0.0002500633,0.00015691984,0.000090941416,0.00069329375,0.0000014750636],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015137623,0.00017592238,0.01718039,0.00018512219,0.00011465375,0.90915644,0.0017351191,0.0000014686651,0.00010408315,0.000024195977,0.00046342603,0.06934539],"study_design_scores_gemma":[0.0030677028,0.005238123,0.21215664,0.002909462,0.00024423716,0.7179723,0.0028182156,0.00045344786,0.00016514512,0.00043172447,0.054247733,0.00029529975],"about_ca_topic_score_codex":0.0006195853,"about_ca_topic_score_gemma":0.00020425563,"teacher_disagreement_score":0.19497624,"about_ca_system_score_codex":0.000090082394,"about_ca_system_score_gemma":0.0011316685,"threshold_uncertainty_score":0.35563025},"labels":[],"label_agreement":null},{"id":"W4392453313","doi":"10.1016/j.jtocrr.2024.100660","title":"Improving Lung Cancer Screening Selection: The HUNT Lung Cancer Risk Model for Ever-Smokers Versus the NELSON and 2021 United States Preventive Services Task Force Criteria in the Cohort of Norway: A Population-Based Prospective Study","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Helse Midt-Norge; Norges Teknisk-Naturvitenskapelige Universitet","keywords":"Task force; Lung cancer; Cohort; Selection (genetic algorithm); Medicine; Cancer; Cohort study; Lung cancer screening; Task (project management); Demography; Environmental health; Oncology; Family medicine; Internal medicine; Political science; Computer science; Economics; Public administration; Management; Sociology; Artificial intelligence","score_opus":0.050971132522593325,"score_gpt":0.46907200042543595,"score_spread":0.4181008679028426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392453313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682547,0.0047015552,0.00019614623,0.0031899686,0.0001856272,0.004806397,0.00006702618,0.000011059631,0.000016758871],"genre_scores_gemma":[0.9951037,0.0016161645,0.000066518165,0.00008436191,0.00021512175,0.0026736036,0.00003205203,0.00001933905,0.00018912787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748015,0.00044583465,0.00058207504,0.00054492924,0.0006605767,0.00028644013],"domain_scores_gemma":[0.9966021,0.0023479739,0.0001898315,0.0002652521,0.00051618344,0.000078631194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004657919,0.00015212531,0.0003192433,0.000102213366,0.00042245793,0.00013425389,0.00007782023,0.00007411617,0.00001917391],"category_scores_gemma":[0.00036495426,0.000069309004,0.000105409614,0.0005654003,0.00016603047,0.00009912336,0.00008128622,0.00052498875,4.57654e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011812419,0.00026748882,0.98717594,0.00046728272,0.00083658716,0.00003827669,0.0033276388,0.0025629692,0.0000047984922,0.0000101478245,0.00037444837,0.003753191],"study_design_scores_gemma":[0.0011322706,0.00045657184,0.5480716,0.00046156498,0.00055955193,0.000002558535,0.0015570233,0.44754055,0.000015260146,0.00010176436,0.000047403475,0.00005389443],"about_ca_topic_score_codex":0.045100097,"about_ca_topic_score_gemma":0.015712496,"teacher_disagreement_score":0.44497758,"about_ca_system_score_codex":0.00022136682,"about_ca_system_score_gemma":0.00044257776,"threshold_uncertainty_score":0.96125865},"labels":[],"label_agreement":null},{"id":"W4393204492","doi":"10.1016/j.jtocrr.2024.100669","title":"Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Sanofi Genzyme; AstraZeneca Korea; EMD Serono; Genentech; Daiichi-Sankyo; G1 Therapeutics; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Sanofi; Amgen; American Association for Cancer Research; Eli Lilly and Company; Bristol-Myers Squibb; Seagen; LUNGevity Foundation; Pfizer","keywords":"Osimertinib; Oncology; Medicine; Retrospective cohort study; Cohort; Internal medicine; Mutant; Term (time); Cancer; Epidermal growth factor receptor; Biology; Genetics; Gene; Erlotinib","score_opus":0.10945630966295825,"score_gpt":0.5031910424772752,"score_spread":0.3937347328143169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393204492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942521,0.0011565253,0.00009033028,0.001530055,0.00026236978,0.0004901808,0.000017548238,0.000032310327,0.0021685797],"genre_scores_gemma":[0.9950751,0.0011016626,0.00020522256,0.000040256462,0.00015196315,0.00003344049,0.000038299127,0.000019103478,0.003334938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979899,0.00010665417,0.0006277846,0.00035318092,0.00068868254,0.00023378144],"domain_scores_gemma":[0.9984309,0.0005447527,0.00007907847,0.00028828267,0.00039303675,0.0002639262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018433224,0.00009712295,0.0003776141,0.00012078689,0.00006730251,0.0000460365,0.000030470217,0.00005611594,0.000116508],"category_scores_gemma":[0.0005513293,0.00005298409,0.00008951641,0.000275555,0.00045037514,0.00005682743,0.000048839553,0.00035888434,0.000009171876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028449297,0.0006269795,0.87991023,0.0010556272,0.0008261463,0.025044085,0.00026200165,1.4414587e-7,0.0001735409,0.00023890755,0.00053874194,0.091039084],"study_design_scores_gemma":[0.0006412545,0.0016578182,0.98875105,0.0010564029,0.0004798061,0.0013735825,0.000077152115,0.00004724607,0.00024174641,0.00031897597,0.005256878,0.00009808042],"about_ca_topic_score_codex":0.00017763268,"about_ca_topic_score_gemma":0.00007179462,"teacher_disagreement_score":0.10884081,"about_ca_system_score_codex":0.000038648002,"about_ca_system_score_gemma":0.00069276465,"threshold_uncertainty_score":0.21606286},"labels":[],"label_agreement":null},{"id":"W4394015790","doi":"10.1016/j.jtocrr.2024.100674","title":"Treating Tobacco Dependency in National Health Service Workers in Greater Manchester: An Evaluation of a Bespoke Digital Service","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Physicians for a Smoke-Free Canada","funders":"","keywords":"Bespoke; Dependency (UML); General partnership; Service (business); Health care; Health services; Nursing; Population; Medicine; Business; Environmental health; Marketing; Economic growth; Advertising; Engineering","score_opus":0.35745906115526754,"score_gpt":0.5499180261932134,"score_spread":0.19245896503794585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394015790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953219,0.00016704213,0.0000015581919,0.0029295643,0.00011508013,0.0004957103,0.0000040030445,0.000019002755,0.0009461346],"genre_scores_gemma":[0.99945676,0.000031624302,0.000034315657,0.00013071323,0.00012485804,0.000050470127,0.000071463845,0.0000121866215,0.000087580425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963298,0.00033669852,0.00089033274,0.00042704315,0.001785118,0.0002309951],"domain_scores_gemma":[0.9984457,0.00028601885,0.00008878163,0.00018667619,0.00084717356,0.00014564166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013165933,0.00008429447,0.00025102263,0.00032846778,0.000039064427,0.00007112056,0.000041488765,0.00014336528,0.0000541403],"category_scores_gemma":[0.00087201496,0.00006563591,0.000042498494,0.00078499445,0.000051446565,0.00029205676,0.000053273034,0.00050016295,0.000002090559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100618476,0.00019173806,0.9196029,0.0001924131,0.000010631693,0.00018687187,0.00088228774,0.0000116112515,0.000018468592,0.000005989435,0.00003507419,0.0787614],"study_design_scores_gemma":[0.00070059835,0.00024455276,0.9942375,0.0009435484,0.0000139858175,0.00012248187,0.0010356258,0.0017196365,0.000025874677,0.00083661627,0.00006077799,0.000058811893],"about_ca_topic_score_codex":0.0014674343,"about_ca_topic_score_gemma":0.0017011946,"teacher_disagreement_score":0.07870259,"about_ca_system_score_codex":0.00021417861,"about_ca_system_score_gemma":0.0013466683,"threshold_uncertainty_score":0.4563076},"labels":[],"label_agreement":null},{"id":"W4396978955","doi":"10.1016/j.jtocrr.2024.100682","title":"Reproducibility of Assessment of Lepidic (Noninvasive) Patterns in Lung Adenocarcinoma With Cytokeratin Immunostain Compared With Hematoxylin and Eosin and the Proposed New International Association for the Study of Lung Cancer (IASLC) Algorithm","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Medicine; Lung cancer; Cytokeratin; Adenocarcinoma; H&E stain; Pathology; Lung; Reproducibility; Stain; Oncology; Radiology; Cancer; Internal medicine; Immunohistochemistry; Staining","score_opus":0.06632887354129716,"score_gpt":0.46802618443918176,"score_spread":0.40169731089788463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396978955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482645,0.005351679,0.00009948963,0.0061915163,0.000078307836,0.003397537,0.000022074018,0.0000047849494,0.00002815484],"genre_scores_gemma":[0.9975737,0.0016253036,0.0002328658,0.000015476158,0.00008318578,0.00026684348,0.000008922828,0.0000102734275,0.00018343021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721134,0.0003537427,0.00085061055,0.0006276766,0.00080526783,0.0001513652],"domain_scores_gemma":[0.9961274,0.0024507432,0.00031822335,0.00047994484,0.00055805594,0.000065583656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009548192,0.00010383352,0.00052645034,0.00007161879,0.00006584299,0.000038754588,0.00005358857,0.000050665352,0.000009285203],"category_scores_gemma":[0.00085833005,0.000045027908,0.000052242667,0.00017293976,0.00030066652,0.00005098756,0.000098311706,0.00030771503,8.058144e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009265175,0.0008239932,0.98986727,0.00065039785,0.0010071053,0.00010902033,0.0016708509,0.000011878005,0.0000150269725,0.000035414392,0.00026417253,0.004618339],"study_design_scores_gemma":[0.0057579535,0.001489906,0.98262006,0.0011207837,0.00032375054,0.000034729866,0.0013672861,0.0067833187,0.00034794124,0.00007071513,0.000033913264,0.0000496673],"about_ca_topic_score_codex":0.006227848,"about_ca_topic_score_gemma":0.0014728472,"teacher_disagreement_score":0.012747242,"about_ca_system_score_codex":0.0001874463,"about_ca_system_score_gemma":0.0008653131,"threshold_uncertainty_score":0.9414685},"labels":[],"label_agreement":null},{"id":"W4396979010","doi":"10.1016/j.jtocrr.2024.100691","title":"EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Shionogi; Astellas Pharma; Kyowa Hakko Kirin; Eisai; Chugai Pharmaceutical; Celltrion; Kissei; Taiho Pharmaceutical; Genomic Health; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Li–Fraumeni syndrome; Germline; Family history; Genetic testing; Medicine; Germline mutation; Oncology; Lung cancer; Adenocarcinoma; Internal medicine; Cancer research; Mutation; Genetics; Cancer; Biology; Gene","score_opus":0.08971594190306834,"score_gpt":0.44677033427935625,"score_spread":0.3570543923762879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396979010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278605,0.002122993,0.000046101748,0.0016543018,0.00017533376,0.002484832,0.000013848525,0.000053902437,0.0006626126],"genre_scores_gemma":[0.9948347,0.000023646055,0.00076851336,0.00011296342,0.00011141132,0.00051248,0.00006732303,0.000039106017,0.0035298609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973093,0.00013436035,0.00078459096,0.0007024743,0.00067266414,0.00039658055],"domain_scores_gemma":[0.9971493,0.0011458183,0.00013342287,0.00039973904,0.0009130102,0.00025873864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00229922,0.00017464154,0.00039600182,0.00016913882,0.0002116054,0.00006655481,0.00003913278,0.00010215172,0.000018405866],"category_scores_gemma":[0.0014527595,0.00007591354,0.00007099567,0.00047009115,0.0004579265,0.00011530121,0.000056792775,0.00063774735,0.0000013397913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054524216,0.0004145209,0.56299806,0.00021709947,0.00036411354,0.4277586,0.00057643076,0.0000043315763,0.00000530959,0.000011484648,0.0031007528,0.0040040337],"study_design_scores_gemma":[0.0036137246,0.0057030693,0.88148266,0.0010345989,0.00043299876,0.09824274,0.00050860905,0.0014313546,0.000004506733,0.000107304244,0.0072383555,0.00020005245],"about_ca_topic_score_codex":0.0009772067,"about_ca_topic_score_gemma":0.00018182381,"teacher_disagreement_score":0.32951587,"about_ca_system_score_codex":0.0004487188,"about_ca_system_score_gemma":0.0018005058,"threshold_uncertainty_score":0.319402},"labels":[],"label_agreement":null},{"id":"W4399705795","doi":"10.1016/j.jtocrr.2024.100696","title":"Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Center (category theory); Tertiary care; Stage (stratigraphy); Medicine; Lung cancer; Cancer; Clinical trial; Oncology; Internal medicine; Family medicine","score_opus":0.2734519420320826,"score_gpt":0.6070180270986795,"score_spread":0.33356608506659685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399705795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830275,0.0026907409,0.000008883304,0.0049977372,0.00080150645,0.0054863296,0.0001028093,0.00009994284,0.0027845476],"genre_scores_gemma":[0.98159075,0.003372033,0.0002985513,0.00034479905,0.0010914295,0.00048836216,0.00020590116,0.00006828593,0.012539872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98835766,0.0022139174,0.0042458186,0.0019781648,0.0022255697,0.0009788669],"domain_scores_gemma":[0.9837795,0.010917179,0.00042091077,0.0013491401,0.002634048,0.00089923094],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0534175,0.00029367252,0.0018505469,0.00032831327,0.0002414683,0.00012652545,0.000120431054,0.0002897941,0.0000843251],"category_scores_gemma":[0.06718991,0.00017205378,0.00062917237,0.0005715832,0.0015491392,0.00015088469,0.0006962047,0.0016687255,0.000009227088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045311283,0.0006881769,0.9088591,0.0014351482,0.0003430271,0.01280438,0.0001482223,1.6783513e-7,0.0000053170947,0.00001532667,0.05074304,0.020427013],"study_design_scores_gemma":[0.0038930487,0.0015682608,0.83713347,0.0011899249,0.00008569286,0.00008419221,0.00009755193,0.000028125867,0.000026726586,0.00020167467,0.15551849,0.0001728471],"about_ca_topic_score_codex":0.00066166965,"about_ca_topic_score_gemma":0.001787226,"teacher_disagreement_score":0.10477545,"about_ca_system_score_codex":0.0005015071,"about_ca_system_score_gemma":0.0014478792,"threshold_uncertainty_score":0.9747059},"labels":[],"label_agreement":null},{"id":"W4399705963","doi":"10.1016/j.jtocrr.2024.100697","title":"Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Cancer Research Society; Cancer Research Foundation","keywords":"Medicine; Oncology; Lung cancer; Internal medicine","score_opus":0.0655007970993161,"score_gpt":0.487848837616346,"score_spread":0.4223480405170299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399705963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936469,0.00033218483,0.000008345058,0.0014343258,0.00039319185,0.0024688072,0.0000739047,0.000060952305,0.0015813533],"genre_scores_gemma":[0.979966,0.0024292145,0.0005081569,0.00010438789,0.00019575347,0.00041551344,0.00021430098,0.000041138228,0.01612554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965703,0.00015217651,0.0012813263,0.00097018015,0.00059806206,0.0004279588],"domain_scores_gemma":[0.9971964,0.001416107,0.00013595613,0.00040527855,0.00039281498,0.00045346364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019567893,0.0001469673,0.00070431916,0.00010765647,0.00016893701,0.0002592442,0.000033115663,0.00014576007,0.000049478967],"category_scores_gemma":[0.0012637306,0.00012195807,0.00019576003,0.0002453737,0.00036377113,0.00012019046,0.000059366706,0.000384172,0.0000013205021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017437553,0.0010928498,0.79190785,0.00010948517,0.0003544719,0.008063645,0.000044680055,8.9255664e-8,2.1183139e-7,0.000003835989,0.0017127851,0.19653572],"study_design_scores_gemma":[0.0049538435,0.0030547432,0.9447161,0.0006802463,0.00022484601,0.00023665093,0.00005573835,0.000016935257,5.177454e-7,0.000236035,0.04569308,0.0001312713],"about_ca_topic_score_codex":0.038549975,"about_ca_topic_score_gemma":0.22937283,"teacher_disagreement_score":0.19640446,"about_ca_system_score_codex":0.00016496753,"about_ca_system_score_gemma":0.00059684936,"threshold_uncertainty_score":0.9678524},"labels":[],"label_agreement":null},{"id":"W4400412031","doi":"10.1016/j.jtocrr.2024.100702","title":"Identifying Novel Germline Mutations and Copy Number Variations in Patients With SCLC","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; St Mary's Hospital Centre; Western University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Canadian Institutes of Health Research; Weill Cornell Medical College; University of Toronto; Memorial Sloan-Kettering Cancer Center","keywords":"Germline; Germline mutation; Genetics; Biology; Copy-number variation; Mutation; Affect (linguistics); Oncology; Medicine; Gene; Genome; Psychology","score_opus":0.1449493709868936,"score_gpt":0.5350573537025527,"score_spread":0.3901079827156591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400412031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907438,0.00068073894,0.00022855577,0.0045247213,0.00018006416,0.00084928476,0.000011503158,0.00004690232,0.0027344306],"genre_scores_gemma":[0.99597543,0.00048785325,0.001206089,0.000053284974,0.00017272522,0.00008463208,0.00002617084,0.00001873902,0.0019750637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973777,0.00010819829,0.000568824,0.00051223976,0.0010848246,0.00034820492],"domain_scores_gemma":[0.99786496,0.0009703018,0.000042353866,0.00023284984,0.0006154465,0.0002740843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033816113,0.00009738729,0.00028350466,0.00021265885,0.00018472786,0.00013014046,0.000033401775,0.00008593704,0.000075525015],"category_scores_gemma":[0.0031008816,0.000062916784,0.00004194719,0.0006043784,0.00062638195,0.00015757309,0.00019576326,0.0008190308,0.000013561459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001442868,0.00035473748,0.99155533,0.00030106504,0.00013519371,0.0007774185,0.000276887,4.3539683e-7,0.000017687069,0.00048120314,0.0017708361,0.004184941],"study_design_scores_gemma":[0.0012929307,0.0003192385,0.98843503,0.00060173473,0.000038038874,0.00008446437,0.00007894545,0.00022057253,0.000009543988,0.0014942313,0.0073440145,0.00008126897],"about_ca_topic_score_codex":0.00024671483,"about_ca_topic_score_gemma":0.00012845405,"teacher_disagreement_score":0.005573178,"about_ca_system_score_codex":0.00008139478,"about_ca_system_score_gemma":0.0004530851,"threshold_uncertainty_score":0.3712269},"labels":[],"label_agreement":null},{"id":"W4403411452","doi":"10.1016/j.jtocrr.2024.100737","title":"CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Technologique des Résidus Industriels; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Lung cancer; Medicine; Cancer; Immunotherapy; Cancer research; Lung; Oncology; Internal medicine","score_opus":0.09651927422717367,"score_gpt":0.4826450913431923,"score_spread":0.3861258171160186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403411452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933657,0.0035360707,0.0000084945195,0.0011846356,0.0001633633,0.0013635616,8.2206765e-7,0.000018644376,0.00035870948],"genre_scores_gemma":[0.9968574,0.0023862687,0.000032593507,0.00004489989,0.00004546467,0.00018808471,0.0000036759295,0.000016897746,0.00042472777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997718,0.00022304643,0.0008019427,0.00038682672,0.0006618511,0.00020836631],"domain_scores_gemma":[0.99901867,0.00037084037,0.0000933049,0.0002266222,0.00023740433,0.000053153686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039892117,0.00009429265,0.00033020784,0.00036974263,0.000036771104,0.000026235306,0.000037948936,0.0000633597,0.000053085965],"category_scores_gemma":[0.00022710954,0.0000623415,0.000033235036,0.000957153,0.0001917407,0.00012651908,0.000026232938,0.00054758013,2.2929498e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015547352,0.004218889,0.8547332,0.0002641556,0.00017886683,0.00086081884,0.0008501554,0.000006807494,0.009167294,0.000025926689,0.00017998296,0.11396652],"study_design_scores_gemma":[0.0063604685,0.008733421,0.9811403,0.0012200022,0.000011870498,0.000033027787,0.00046882787,0.0003393131,0.000351924,0.00017836425,0.0010778521,0.00008461068],"about_ca_topic_score_codex":0.0030916154,"about_ca_topic_score_gemma":0.0014584092,"teacher_disagreement_score":0.12640709,"about_ca_system_score_codex":0.00014149252,"about_ca_system_score_gemma":0.0004147636,"threshold_uncertainty_score":0.46736184},"labels":[],"label_agreement":null},{"id":"W4404290023","doi":"10.1016/j.jtocrr.2024.100765","title":"Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca; LUNGevity Foundation","keywords":"Oncology; Medicine; Internal medicine; Disease; Lung cancer; Cancer; Cancer research; Lung; Pathology","score_opus":0.09377657879051397,"score_gpt":0.5098656703436437,"score_spread":0.41608909155312973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404290023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423563,0.001427257,0.00002723976,0.0033545326,0.00007462412,0.000719362,0.000040061248,0.000048646732,0.00007264616],"genre_scores_gemma":[0.9978197,0.0007876929,0.0000728013,0.0002113704,0.00009090981,0.00013511555,0.00025269357,0.000022023942,0.0006076459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685663,0.0003439124,0.0007019513,0.000736093,0.0009536248,0.00040780383],"domain_scores_gemma":[0.99731666,0.0004288705,0.000085129206,0.0003529325,0.00017932485,0.0016370632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020077478,0.00017490679,0.0004898227,0.0005461131,0.00012049888,0.00007232315,0.00004226042,0.00010601547,0.00008110829],"category_scores_gemma":[0.0013829658,0.00010116313,0.00009358221,0.00091804884,0.000532476,0.00014182118,0.00006594052,0.00059764495,0.0000022035472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027960516,0.00050452433,0.96971685,0.00019084693,0.0010221055,0.008598195,0.00036841634,0.000003151308,0.0000010321886,0.000016340011,0.00006693312,0.019231986],"study_design_scores_gemma":[0.0015011239,0.0010288265,0.9917137,0.00076593866,0.0019498479,0.00008608502,0.000342363,0.001562848,0.000008171787,0.00023148455,0.0006700803,0.00013950035],"about_ca_topic_score_codex":0.000343216,"about_ca_topic_score_gemma":0.00018938414,"teacher_disagreement_score":0.021996867,"about_ca_system_score_codex":0.00014374012,"about_ca_system_score_gemma":0.0013352395,"threshold_uncertainty_score":0.4125313},"labels":[],"label_agreement":null},{"id":"W4404630193","doi":"10.1016/j.jtocrr.2024.100772","title":"Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors","year":2024,"lang":"en","type":"review","venue":"JTO Clinical and Research Reports","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Myasthenia gravis; Medicine; Immunology","score_opus":0.13199170105698427,"score_gpt":0.4742182047809884,"score_spread":0.34222650372400415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404630193","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0449995,0.9502662,1.0023489e-7,0.00020225931,0.00028898707,0.00249791,0.000015360265,0.00006387368,0.0016658419],"genre_scores_gemma":[0.0076200836,0.9856849,0.000041346062,0.000015188168,0.00046115558,0.00020432414,0.00021016186,0.0001290187,0.0056338576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924223,0.000621071,0.0032197705,0.0013387293,0.0016347346,0.0007634123],"domain_scores_gemma":[0.9970558,0.0003687985,0.00044444515,0.0009622113,0.00052455324,0.0006441537],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0066403183,0.00055031397,0.0032172266,0.0007630406,0.00010177478,0.0001126991,0.00013467422,0.00076953054,0.000082381004],"category_scores_gemma":[0.0013330622,0.00028053753,0.000815896,0.0012650159,0.00070874015,0.000052372245,0.00038617864,0.0033330705,0.00011241736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031228617,0.0011878766,0.049855914,0.01622824,0.0004773726,0.014651641,0.000047748435,6.432631e-9,2.6080758e-7,0.000028077704,0.0021769411,0.91503364],"study_design_scores_gemma":[0.0010457758,0.0024101983,0.01582584,0.040976807,0.00072345533,0.00084607897,0.000013750586,0.0000013411086,0.000001245829,0.00018939203,0.93761784,0.00034828615],"about_ca_topic_score_codex":0.00030426023,"about_ca_topic_score_gemma":0.000030412139,"teacher_disagreement_score":0.9354409,"about_ca_system_score_codex":0.0001556533,"about_ca_system_score_gemma":0.0009512835,"threshold_uncertainty_score":0.99996465},"labels":[],"label_agreement":null},{"id":"W4405556325","doi":"10.1016/j.jtocrr.2024.100781","title":"Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research","year":2024,"lang":"en","type":"review","venue":"JTO Clinical and Research Reports","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Chonnam National University; Princess Margaret Cancer Foundation","keywords":"Lung cancer; Oncology; Medicine; Cancer; Internal medicine","score_opus":0.5703970070624337,"score_gpt":0.6704910618664188,"score_spread":0.10009405480398514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405556325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035693447,0.9891358,0.000004896029,0.0019267951,0.00013874736,0.0072133485,0.00027198088,0.000015802598,0.0009356913],"genre_scores_gemma":[0.00025343135,0.977686,0.00009108346,0.000057767455,0.00060470565,0.012262382,0.0003980066,0.000115637784,0.008531027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98947656,0.0036150045,0.0018747884,0.0021860932,0.0012253424,0.0016222139],"domain_scores_gemma":[0.99395436,0.0017001046,0.00020528343,0.0013931186,0.0020788894,0.00066826184],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.03295322,0.0004105362,0.0019203679,0.0008098003,0.0005958225,0.00022320675,0.00052294886,0.0009944292,0.00003181653],"category_scores_gemma":[0.0053198454,0.00029199044,0.0004983339,0.0012187727,0.0018469928,0.000018233399,0.002104998,0.0031014336,0.000009570128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024235444,0.00069369265,0.00012216192,0.071323045,0.0011084799,0.00051158573,0.00005019402,2.3769556e-7,0.000080883816,0.000603655,0.21001169,0.71525204],"study_design_scores_gemma":[0.0005341357,0.00088876014,0.000012878619,0.010144361,0.00028993218,0.00014612608,0.000020477895,0.000011281542,0.000007188229,0.0033558721,0.9843182,0.00027077197],"about_ca_topic_score_codex":0.0013543521,"about_ca_topic_score_gemma":0.0022389297,"teacher_disagreement_score":0.77430654,"about_ca_system_score_codex":0.00045295316,"about_ca_system_score_gemma":0.005382678,"threshold_uncertainty_score":0.9999532},"labels":[],"label_agreement":null},{"id":"W4406185437","doi":"10.1016/j.jtocrr.2025.100789","title":"Cannabidiol Vaping–Associated Multifocal NSCLC in a 24-Year-Old Female: A Case Report","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Lung cancer; Lung; Oncology; Surgery; Internal medicine","score_opus":0.0836007197794546,"score_gpt":0.45595301075823325,"score_spread":0.37235229097877864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406185437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98489404,0.00082299777,0.0000115992225,0.003908235,0.00069644843,0.00090061437,0.0000134543625,0.00006221485,0.0086903805],"genre_scores_gemma":[0.9777194,0.00022867073,0.00007876909,0.00041568035,0.00029977137,0.000091692156,0.000032756983,0.000020257585,0.021112993],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99570847,0.0004529209,0.0015065722,0.0008698906,0.00080886605,0.00065327407],"domain_scores_gemma":[0.9973846,0.0004893024,0.00017496305,0.00063624966,0.00077069487,0.0005441545],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007232814,0.00018972876,0.00068173633,0.00032807575,0.00021700676,0.000060582515,0.00007479133,0.00040796542,0.00007957041],"category_scores_gemma":[0.013469567,0.00014942724,0.00029254213,0.0007000175,0.0005947754,0.000079909645,0.00028999415,0.0013607583,0.000009265534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001977185,0.0010031094,0.34697774,0.00024008019,0.00011198412,0.6320562,0.00008338557,6.6245536e-7,0.000082675055,0.00013495119,0.013756534,0.003575483],"study_design_scores_gemma":[0.007460376,0.006736245,0.786772,0.0070636193,0.00039535115,0.12143889,0.0023286596,0.0022563643,0.0001337062,0.0029777372,0.061575342,0.0008617107],"about_ca_topic_score_codex":0.0041273157,"about_ca_topic_score_gemma":0.0005866598,"teacher_disagreement_score":0.5106173,"about_ca_system_score_codex":0.00020866281,"about_ca_system_score_gemma":0.0012069722,"threshold_uncertainty_score":0.9948404},"labels":[],"label_agreement":null},{"id":"W4407357835","doi":"10.1016/j.jtocrr.2025.100803","title":"CD5 Immunoreactivity Is Associated With Longer Overall Survival in Thymic Carcinoma: A Brief Report","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Thymic carcinoma; CD5; Carcinoma; Adrenocortical carcinoma; Medicine; Pathology; Oncology; Internal medicine; Cancer research; Thymoma; Lymphoma","score_opus":0.0818800981941174,"score_gpt":0.43183146762000185,"score_spread":0.34995136942588445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407357835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97193164,0.00041512726,0.000005496911,0.0030831082,0.00020507262,0.0006233637,0.000004194949,0.000035204146,0.023696782],"genre_scores_gemma":[0.9817397,0.00014320872,0.000031132415,0.00029372537,0.00011512864,0.00003610549,0.000029930048,0.000020831258,0.017590268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957623,0.00046298513,0.0011537566,0.0008518474,0.0011759152,0.0005932029],"domain_scores_gemma":[0.9969938,0.0009819821,0.00023062625,0.0008228133,0.00068022177,0.00029058746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010388225,0.00019286644,0.00084107014,0.00024882107,0.00014527973,0.00006311148,0.00008240189,0.00031934207,0.00009497065],"category_scores_gemma":[0.0056511564,0.00012865201,0.00017410761,0.0006067115,0.0005699194,0.000089345645,0.00023008237,0.0014747321,0.000004161733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000767785,0.0009301635,0.9506759,0.00006128592,0.00016473564,0.040860463,0.00008271454,8.2566466e-8,0.00017101072,0.0001633072,0.0036300176,0.002492523],"study_design_scores_gemma":[0.0021517582,0.0005373315,0.98319674,0.0003843978,0.00004688344,0.0012255464,0.0000536645,0.00004238652,0.00011946693,0.0021152713,0.0099889,0.00013763839],"about_ca_topic_score_codex":0.002375583,"about_ca_topic_score_gemma":0.00038805613,"teacher_disagreement_score":0.039634917,"about_ca_system_score_codex":0.00012469463,"about_ca_system_score_gemma":0.001089356,"threshold_uncertainty_score":0.67653704},"labels":[],"label_agreement":null},{"id":"W4407406710","doi":"10.1016/j.jtocrr.2025.100802","title":"Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Northeast Cancer Centre","funders":"","keywords":"Mesothelioma; Medicine; Real world data; Asbestos; Oncology; Pleural disease; Internal medicine; Pathology; Respiratory disease; Computer science; Lung; Data science","score_opus":0.04555674987359959,"score_gpt":0.43708879281529617,"score_spread":0.3915320429416966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639827,0.0003282333,3.03878e-7,0.001784833,0.000023615594,0.0006859825,0.0000101910055,0.000013921772,0.0007546262],"genre_scores_gemma":[0.9986921,0.00036206847,0.00007636955,0.0001988676,0.000016097463,0.000031796397,0.000042575015,0.0000069827793,0.00057313615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978731,0.00023369626,0.00065547327,0.00045530047,0.0004774294,0.0003049467],"domain_scores_gemma":[0.99910074,0.0003271659,0.00008364299,0.00019358497,0.00006263773,0.00023220645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016185725,0.00010122819,0.00035579552,0.00023952626,0.00008270455,0.000014917839,0.00002608635,0.000050257855,0.000016491189],"category_scores_gemma":[0.00047484742,0.000064254484,0.000031688127,0.00040045998,0.00035578365,0.00006288031,0.00010516686,0.00028886247,7.119206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018481615,0.0006797791,0.9716323,0.00017186717,0.000017460581,0.0002777936,0.000024707104,7.173084e-7,0.0000067059605,0.000018403412,0.00014653262,0.025175583],"study_design_scores_gemma":[0.0020147737,0.00060205575,0.9957628,0.00081217586,0.000007739389,0.0000049271016,0.000033782104,0.00007016631,0.000016344775,0.00032943982,0.00028623475,0.000059551985],"about_ca_topic_score_codex":0.001637001,"about_ca_topic_score_gemma":0.0013890803,"teacher_disagreement_score":0.02511603,"about_ca_system_score_codex":0.00008745879,"about_ca_system_score_gemma":0.0001930649,"threshold_uncertainty_score":0.2620222},"labels":[],"label_agreement":null},{"id":"W4408051654","doi":"10.1016/j.jtocrr.2025.100816","title":"Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; Winship Cancer Institute; International Association for the Study of Lung Cancer","keywords":"Oncology; Medicine; Biomarker discovery; Biomarker; Internal medicine; Medical physics; Biology; Proteomics","score_opus":0.2424729015559155,"score_gpt":0.6030156848792918,"score_spread":0.3605427833233763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408051654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807763,0.00008517012,0.000034199602,0.0004373445,0.000076619304,0.0009838474,0.00025527383,0.0000014891518,0.000048438982],"genre_scores_gemma":[0.99882764,0.0005669421,0.00023337221,0.000020651118,0.000028666856,0.00008151238,0.00008983356,0.000004092933,0.00014731023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978473,0.00020673746,0.0011169427,0.0003241394,0.00039761758,0.00010725976],"domain_scores_gemma":[0.9945949,0.0033436841,0.0008139013,0.00034943462,0.0008500821,0.000048049023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027940094,0.00006471761,0.0006624176,0.00012148855,0.00003725152,0.0000061440437,0.00007231515,0.00005603252,0.0000029937305],"category_scores_gemma":[0.0015517907,0.000034496043,0.0000891309,0.000478815,0.00025822764,0.00007693419,0.000107001564,0.00011397996,1.7903525e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077255006,0.0032768762,0.90114343,0.000057193116,0.0062496457,0.000002517215,0.0002992372,0.000026224072,0.000004781686,0.000002101761,0.000051844552,0.08811362],"study_design_scores_gemma":[0.003518759,0.003349532,0.9852848,0.0001117549,0.0021811344,1.4240237e-7,0.00089531246,0.004501976,0.0000041864782,0.000005410823,0.000120409066,0.000026573642],"about_ca_topic_score_codex":0.026733106,"about_ca_topic_score_gemma":0.010175383,"teacher_disagreement_score":0.088087045,"about_ca_system_score_codex":0.00018258719,"about_ca_system_score_gemma":0.0009839657,"threshold_uncertainty_score":0.97974795},"labels":[],"label_agreement":null},{"id":"W4408389791","doi":"10.1016/j.jtocrr.2025.100824","title":"Corrigendum to ‘Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research’ [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]","year":2025,"lang":"en","type":"review","venue":"JTO Clinical and Research Reports","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Lung cancer; Volume (thermodynamics); Oncology; Medicine; Clinical Oncology; Engineering ethics; Medical physics; Cancer; Internal medicine; Engineering","score_opus":0.46982019649651174,"score_gpt":0.6395786054916736,"score_spread":0.1697584089951618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408389791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012304396,0.97579587,0.000024053023,0.004919716,0.00059176376,0.015305186,0.00034624786,0.000028962659,0.0017577456],"genre_scores_gemma":[0.0004840128,0.9342499,0.0003137876,0.00022194555,0.0011140443,0.0136382785,0.00042500297,0.00014767254,0.049405374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97201884,0.011858457,0.004833345,0.004745023,0.003205474,0.003338845],"domain_scores_gemma":[0.9811067,0.0048030405,0.00056748826,0.003282737,0.00812241,0.002117631],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaresearch","sts","research_integrity"],"category_scores_codex":[0.10781212,0.0007528718,0.0037710944,0.0018361711,0.0015999642,0.0004482005,0.0009860444,0.0020218247,0.00012509257],"category_scores_gemma":[0.044748146,0.0006101645,0.0007086585,0.0027474894,0.004402237,0.000053449578,0.005572797,0.0059720515,0.000018384295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006652589,0.0010231766,0.001740209,0.02505205,0.000754271,0.0011661109,0.00006640793,3.731562e-7,0.000039292863,0.00013344247,0.4968565,0.4725029],"study_design_scores_gemma":[0.0010524425,0.0023771052,0.00025263,0.010976939,0.00023528752,0.0002683342,0.00007590293,0.000015598402,0.000013698457,0.002318345,0.981891,0.0005227541],"about_ca_topic_score_codex":0.004075951,"about_ca_topic_score_gemma":0.004663632,"teacher_disagreement_score":0.48503447,"about_ca_system_score_codex":0.0008123282,"about_ca_system_score_gemma":0.013740053,"threshold_uncertainty_score":0.99969983},"labels":[],"label_agreement":null},{"id":"W4409686990","doi":"10.1016/j.jtocrr.2025.100837","title":"Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; McGill University Health Centre; Institut universitaire de cardiologie et de pneumologie de Québec; William Osler Health System; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer Canada; Amgen Canada; AstraZeneca; Pfizer; Amgen","keywords":"Lung cancer; Biomarker; Medicine; Cancer; Oncology; Intensive care medicine; Internal medicine; Biology; Genetics","score_opus":0.24735867700694428,"score_gpt":0.5728935209881609,"score_spread":0.3255348439812167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409686990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74302775,0.0009835692,0.016739296,0.07474465,0.0007212993,0.007896632,0.000018498456,0.00007308359,0.15579522],"genre_scores_gemma":[0.97582996,0.000069788795,0.019220598,0.00063903583,0.000053859658,0.00096701976,0.000003323736,0.000008133126,0.00320827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973538,0.00019555826,0.00081536634,0.0006469789,0.0005658212,0.0004224626],"domain_scores_gemma":[0.9969274,0.0020290983,0.000055908888,0.0002586963,0.0004610779,0.00026783833],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004458625,0.000105273226,0.0003275411,0.00049260206,0.00015279218,0.00007198365,0.00006655905,0.00008180166,0.000009337458],"category_scores_gemma":[0.015578457,0.00007595462,0.000034616285,0.0016527504,0.00012286124,0.00009136729,0.0001721132,0.00036956958,0.0000018646149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001532354,0.0025335273,0.97009605,0.0004985617,0.00011591617,0.00061318144,0.00053554354,0.0000219606,0.000608484,0.0045026913,0.0018409352,0.01847991],"study_design_scores_gemma":[0.00061820453,0.00017669964,0.993796,0.0010771394,0.00010335132,0.00002412359,0.0007717375,0.001648795,0.000009034155,0.00051461067,0.0011619427,0.000098379634],"about_ca_topic_score_codex":0.0013134758,"about_ca_topic_score_gemma":0.00006489662,"teacher_disagreement_score":0.23280221,"about_ca_system_score_codex":0.0002513467,"about_ca_system_score_gemma":0.0004888546,"threshold_uncertainty_score":0.99271375},"labels":[],"label_agreement":null},{"id":"W4410397042","doi":"10.1016/j.jtocrr.2025.100843","title":"Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010–2023): A Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Hôpital Charles-Le Moyne; Lakeridge Health; Cancer Care South East; Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Lung cancer; Oncology; Internal medicine","score_opus":0.1783990665376195,"score_gpt":0.5371745444105063,"score_spread":0.35877547787288677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410397042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93507665,0.035504963,0.002519644,0.01589876,0.00095934846,0.0051790224,0.00017883425,0.000102546794,0.004580214],"genre_scores_gemma":[0.9606212,0.0012466328,0.00028425318,0.0001887713,0.00010680316,0.0009167593,0.00015492251,0.000012807534,0.036467873],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99764687,0.00022702871,0.00061496824,0.00058581756,0.00050130766,0.00042403594],"domain_scores_gemma":[0.9970888,0.0017357472,0.00010693254,0.00044065464,0.0003541474,0.0002737418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009802952,0.00016787462,0.0010215442,0.0002462923,0.00028784134,0.00007943438,0.00003617156,0.00013518854,0.00021198836],"category_scores_gemma":[0.00072701625,0.00009023721,0.0010432635,0.00043516146,0.00023274566,0.000038910413,0.000052331434,0.00020576725,0.0000015848284],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009860041,0.0036230877,0.23970596,0.00035174008,0.5782896,0.00066409266,0.00044845202,0.0000022487734,0.0004398791,0.00037483248,0.03768243,0.13743164],"study_design_scores_gemma":[0.0084679695,0.0047052014,0.27001074,0.00006660485,0.43649724,0.000024488902,0.00029432037,0.00023946006,0.0015892667,0.0046099005,0.27315113,0.0003436975],"about_ca_topic_score_codex":0.0009113777,"about_ca_topic_score_gemma":0.00014225443,"teacher_disagreement_score":0.23546869,"about_ca_system_score_codex":0.00012016063,"about_ca_system_score_gemma":0.0003443955,"threshold_uncertainty_score":0.36797667},"labels":[],"label_agreement":null},{"id":"W4411442686","doi":"10.1016/j.jtocrr.2025.100869","title":"Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, Canada","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Multidisciplinary approach; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Geography; Virology; Political science; Internal medicine; Infectious disease (medical specialty); Disease; Law","score_opus":0.35644501364385783,"score_gpt":0.5822527036511858,"score_spread":0.22580769000732792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411442686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871511,0.0005987254,2.820693e-7,0.010952123,0.00010151908,0.0008070723,0.000010098228,0.000004089908,0.0003750232],"genre_scores_gemma":[0.9968306,0.0017136562,0.0000062799754,0.00038103567,0.000027873435,0.00003626311,0.0000031773843,0.000004792656,0.0009963368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978223,0.00027924665,0.0007723796,0.0003253224,0.0005220821,0.00027869217],"domain_scores_gemma":[0.99534327,0.0034533616,0.00013562528,0.00042503496,0.00016700315,0.00047573043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021945103,0.000104553525,0.00050809176,0.00014696961,0.000099158366,0.000005294856,0.00004452832,0.00013474352,0.000045735447],"category_scores_gemma":[0.006375264,0.000053579533,0.000127879,0.00026909073,0.00038167447,0.000016289356,0.0001150533,0.0004414417,8.552003e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007877234,0.0006444147,0.98339885,0.00019995187,0.00006637174,0.0005236244,0.00032476534,0.00000515486,0.000023127286,0.000008532082,0.0022230397,0.01179445],"study_design_scores_gemma":[0.0014788097,0.0021937133,0.98978186,0.00032671366,0.000024059744,0.000050605337,0.00007589189,0.000012365951,0.000028868117,0.0003795318,0.0056063514,0.000041211475],"about_ca_topic_score_codex":0.98462003,"about_ca_topic_score_gemma":0.98844796,"teacher_disagreement_score":0.017353449,"about_ca_system_score_codex":0.0014081235,"about_ca_system_score_gemma":0.018761573,"threshold_uncertainty_score":0.98680115},"labels":[],"label_agreement":null},{"id":"W4411992223","doi":"10.1016/j.jtocrr.2025.100874","title":"Tobacco Control and Smoking Cessation–Related Content in Oncology Meetings: A Systematic Scoping Review","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Cancer Care Ontario; Princess Margaret Cancer Centre","funders":"University of Toronto; Cancer Care Ontario","keywords":"Smoking cessation; Tobacco control; Medicine; Oncology; Internal medicine; Family medicine; Nursing; Public health; Pathology","score_opus":0.20875359143966715,"score_gpt":0.5214622888793474,"score_spread":0.31270869743968027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411992223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573591,0.02682786,0.00001211977,0.009089582,0.0002857345,0.0031236906,4.751969e-7,0.000034704266,0.0032667443],"genre_scores_gemma":[0.9865532,0.011567933,0.000015356942,0.00109674,0.00003566953,0.00022006368,0.0000047361573,0.0000071671,0.0004991443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963018,0.00086981687,0.0016582056,0.0004134458,0.0005007037,0.0002560839],"domain_scores_gemma":[0.9969221,0.0018877386,0.00027330584,0.00026572793,0.0005088012,0.00014234644],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017417366,0.00009944258,0.00086183404,0.00020707518,0.000116699084,0.000038196005,0.00004012838,0.00023390111,0.000027452148],"category_scores_gemma":[0.014507406,0.000069958216,0.00007646507,0.0003603848,0.00025785825,0.000050872233,0.000078133904,0.00067972316,6.384408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056138873,0.00016080511,0.9584626,0.034092944,0.000060954557,0.0006569354,0.0000698857,1.6930275e-7,0.000033570264,0.00014373507,0.00031268082,0.0059495675],"study_design_scores_gemma":[0.0025016393,0.0003220133,0.5932867,0.40201586,0.00030668365,0.00032864205,0.0003310377,0.000040267205,0.00001744716,0.00055223925,0.00019769638,0.00009978919],"about_ca_topic_score_codex":0.00020434005,"about_ca_topic_score_gemma":0.00006153151,"teacher_disagreement_score":0.3679229,"about_ca_system_score_codex":0.000107641536,"about_ca_system_score_gemma":0.00043584013,"threshold_uncertainty_score":0.99379385},"labels":[],"label_agreement":null},{"id":"W4411992242","doi":"10.1016/j.jtocrr.2025.100876","title":"Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; Takeda Pharmaceutical Company; LUNGevity Foundation","keywords":"Medicine; Lung cancer; Oncology; ROS1; Internal medicine; Term (time); Cancer; Adenocarcinoma","score_opus":0.13808751252396867,"score_gpt":0.5202878453184,"score_spread":0.38220033279443133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411992242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915086,0.0002541916,0.000102561185,0.0013571793,0.00024276944,0.0007067667,0.000017403338,0.000020023765,0.0057904916],"genre_scores_gemma":[0.9873538,0.0005974407,0.00054224423,0.000095375115,0.00009626837,0.00005490721,0.000039126728,0.000011755277,0.011209105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979478,0.00013872456,0.000766866,0.00034804468,0.0005501459,0.0002484349],"domain_scores_gemma":[0.9980636,0.0006297564,0.00010599113,0.00038741663,0.0005946125,0.00021857084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016176086,0.00010481745,0.00049687555,0.00013468089,0.000100883866,0.000027005775,0.000043399345,0.000068612586,0.00008308218],"category_scores_gemma":[0.0012180906,0.000055444983,0.0000783344,0.0003168358,0.00046626487,0.00004453873,0.00007145967,0.00032477113,0.0000017607052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001088453,0.0008945291,0.93855387,0.00046500625,0.00067390205,0.0025409088,0.00012987987,1.6587775e-7,0.0001298942,0.00012527978,0.0016044439,0.053793695],"study_design_scores_gemma":[0.0011835861,0.0014690567,0.98294544,0.00057354337,0.00040596488,0.00020098884,0.00014974609,0.000026994774,0.00018969562,0.0002683029,0.012505666,0.0000810226],"about_ca_topic_score_codex":0.00023990888,"about_ca_topic_score_gemma":0.00019926036,"teacher_disagreement_score":0.053712673,"about_ca_system_score_codex":0.000034448858,"about_ca_system_score_gemma":0.00092787505,"threshold_uncertainty_score":0.22609809},"labels":[],"label_agreement":null},{"id":"W4413015518","doi":"10.1016/j.jtocrr.2025.100887","title":"Lung Cancer in Patients of African Descent: A Transcontinental Review of Epidemiology, Disparities, Outcomes, and Opportunities for Equity in Africa, North America, South America, and the Caribbean","year":2025,"lang":"en","type":"review","venue":"JTO Clinical and Research Reports","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Institutes of Health; Thomas Jefferson University","keywords":"African descent; Equity (law); Epidemiology; Caribbean region; Geography; Health equity; Development economics; Political science; Economic growth; Demography; Medicine; Ethnology; Latin Americans; Economics; History; Sociology; Internal medicine; Health care","score_opus":0.503296054085223,"score_gpt":0.5598815836260794,"score_spread":0.05658552954085638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413015518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002274723,0.99132335,0.000008759029,0.0020146293,0.00008510054,0.0034728318,0.0004983346,0.000005032566,0.00031725893],"genre_scores_gemma":[0.012085724,0.98654324,0.00009112632,0.00039008577,0.00003968488,0.00052139146,0.00012632004,0.00001609651,0.00018633006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99311686,0.0015682968,0.0033559252,0.0006979802,0.0006456173,0.00061531033],"domain_scores_gemma":[0.9925938,0.005088684,0.0011153676,0.0004664716,0.00044314036,0.00029249204],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.009304954,0.0003228772,0.004867398,0.00027968257,0.000074697826,0.000011133408,0.00017937852,0.00023457936,0.000011090038],"category_scores_gemma":[0.012492275,0.00018404085,0.00050758896,0.00052720954,0.0028206469,0.00005676959,0.00042511968,0.0010339768,3.3053315e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027699192,0.00011162465,0.35581142,0.07936958,0.00015213135,0.000052525564,0.00011382032,7.346232e-8,2.802249e-9,0.000038608385,0.0008792555,0.563194],"study_design_scores_gemma":[0.0041070906,0.0010440233,0.21614717,0.26556948,0.0020520915,0.000030742616,0.00064495456,0.000046126654,3.487166e-8,0.00025157965,0.509646,0.00046072295],"about_ca_topic_score_codex":0.0049396297,"about_ca_topic_score_gemma":0.00065156235,"teacher_disagreement_score":0.56273323,"about_ca_system_score_codex":0.00011424479,"about_ca_system_score_gemma":0.0012104494,"threshold_uncertainty_score":0.9998931},"labels":[],"label_agreement":null},{"id":"W4413923563","doi":"10.1016/j.jtocrr.2025.100892","title":"Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]","year":2025,"lang":"en","type":"erratum","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Pembrolizumab; Chemotherapy; Medicine; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.17758127873716026,"score_gpt":0.5096313038910896,"score_spread":0.33205002515392934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413923563","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83629656,0.013115649,0.00082443317,0.04569636,0.05048003,0.035898764,0.0023915896,0.00037355357,0.014923097],"genre_scores_gemma":[0.21898809,0.030880751,0.036714762,0.0059483577,0.023059819,0.00451564,0.005925381,0.0010515763,0.67291564],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98573554,0.0013482146,0.0046267756,0.0023918261,0.0045733494,0.0013243164],"domain_scores_gemma":[0.97523046,0.009363962,0.001600883,0.0011832948,0.01134911,0.0012722743],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024022713,0.0007050808,0.0030481552,0.0008169511,0.0006421065,0.00022552877,0.00024219805,0.00096457545,0.00024224365],"category_scores_gemma":[0.028585708,0.00049044745,0.00055070186,0.0010222972,0.00418843,0.00016970339,0.00025961996,0.0034054832,0.000004136965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07455786,0.0014607279,0.1667454,0.0014194277,0.006672083,0.0034314538,0.00057245255,0.0000025631348,0.000014834335,0.000070996044,0.69890046,0.046151765],"study_design_scores_gemma":[0.024236923,0.014338796,0.44825774,0.0012979632,0.00057370623,0.0005848739,0.00058550684,0.00016510932,0.000018198978,0.00077982154,0.5084995,0.0006618328],"about_ca_topic_score_codex":0.0016641367,"about_ca_topic_score_gemma":0.00091858924,"teacher_disagreement_score":0.65799254,"about_ca_system_score_codex":0.00041358077,"about_ca_system_score_gemma":0.013814766,"threshold_uncertainty_score":0.9997547},"labels":[],"label_agreement":null},{"id":"W4414439969","doi":"10.1016/j.jtocrr.2025.100910","title":"Risk Factors Associated With Incidence of Lung Cancer in Never-Smokers: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"JTO Clinical and Research Reports","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medical Research Council; University College London Hospitals NHS Foundation Trust; Rosetrees Trust; Cancer Research UK; National Institute for Health and Care Research; Entertainment Industry Foundation; American Lung Association; American Association for Cancer Research","keywords":"Lung cancer; Incidence (geometry); Risk factor; Epidemiology; Cancer; Population","score_opus":0.3500971598906501,"score_gpt":0.5673434307207585,"score_spread":0.21724627083010845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414439969","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024016306,0.9941652,0.0000018116095,0.00009529941,0.000027121889,0.0032018363,0.000057147317,0.000011424659,0.000038543592],"genre_scores_gemma":[0.008105567,0.9901811,0.0000035673465,0.000032335298,0.000010705465,0.0005319183,0.000056155408,0.000015455771,0.0010632029],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99263096,0.0023259597,0.0026901143,0.0007076728,0.0013742718,0.0002710309],"domain_scores_gemma":[0.9929054,0.0037954503,0.001629444,0.0006809084,0.0007904274,0.00019841125],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015212539,0.00029820096,0.0090934,0.0005886644,0.000068990834,0.000030285635,0.000099953686,0.00042947783,0.00010974732],"category_scores_gemma":[0.017775,0.00014262684,0.0012570579,0.002345811,0.00030251095,0.00007508171,0.00013546424,0.0013592229,7.6276955e-8],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055123232,0.00013969983,0.23407051,0.7060509,0.057965714,0.000270358,0.00002478698,1.720075e-7,3.960024e-9,0.0000013365466,0.00010679747,0.0013642195],"study_design_scores_gemma":[0.00011289707,0.00009449161,0.030410869,0.20127225,0.7675581,0.000016221627,0.000016214692,0.0000027701399,7.3402504e-8,0.0000072828248,0.0003768432,0.00013196775],"about_ca_topic_score_codex":0.0013352223,"about_ca_topic_score_gemma":0.00029945283,"teacher_disagreement_score":0.7095924,"about_ca_system_score_codex":0.00014683328,"about_ca_system_score_gemma":0.0010126693,"threshold_uncertainty_score":0.9904987},"labels":[],"label_agreement":null},{"id":"W4415016947","doi":"10.1016/j.jtocrr.2025.100918","title":"Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Tyrosine kinase; Alectinib; Tyrosine-kinase inhibitor; Kinase; Drug; Clinical trial","score_opus":0.07263741346254414,"score_gpt":0.4980557138905667,"score_spread":0.42541830042802253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415016947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546565,0.002187116,0.000050822753,0.00609084,0.00027030398,0.0011436947,0.000012926557,0.000022586666,0.0047560576],"genre_scores_gemma":[0.99270654,0.00064736255,0.00046000493,0.00015149287,0.00017055783,0.00006191403,0.000030172236,0.000010201937,0.0057617663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827814,0.00007849391,0.0006781615,0.00038250297,0.00034512978,0.00023757809],"domain_scores_gemma":[0.997903,0.0009687767,0.000098045675,0.00025621158,0.00054380175,0.0002301651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015737707,0.00009564062,0.00037383643,0.0001562027,0.00014605228,0.000022314132,0.000029223547,0.0001284592,0.000018107992],"category_scores_gemma":[0.0025802783,0.00006321204,0.0001058422,0.00028269817,0.00048864074,0.00004020961,0.00010170812,0.00023282287,8.3686524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027204892,0.0054389616,0.60950834,0.0013117507,0.0011995394,0.0013628533,0.0003472514,0.0000014678715,0.0062062135,0.0019920547,0.07869359,0.29121748],"study_design_scores_gemma":[0.019521208,0.00469947,0.7656822,0.0018464086,0.00085308217,0.00019066558,0.00024082883,0.00022613532,0.021841746,0.009332901,0.17527288,0.00029242944],"about_ca_topic_score_codex":0.00015546437,"about_ca_topic_score_gemma":0.000027940721,"teacher_disagreement_score":0.29092506,"about_ca_system_score_codex":0.000035314584,"about_ca_system_score_gemma":0.00045452744,"threshold_uncertainty_score":0.30890206},"labels":[],"label_agreement":null},{"id":"W4415711778","doi":"10.1016/j.jtocrr.2025.100929","title":"Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"Gilead UK and Ireland Corporate Contributions; Gilead Sciences","keywords":"Docetaxel; Quality of life (healthcare); Randomized controlled trial; Phases of clinical research; Chemotherapy; Exploratory analysis","score_opus":0.15520455605900418,"score_gpt":0.5380789188335684,"score_spread":0.3828743627745642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415711778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022144,0.0014202795,0.000041853014,0.0022730317,0.00025285844,0.0030940175,0.0000087311055,0.000014313787,0.002673481],"genre_scores_gemma":[0.99837893,0.00035907762,0.00011997304,0.000112887225,0.000051169587,0.0003033233,0.00001907922,0.000008870346,0.0006466811],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99565345,0.0010657262,0.0017403937,0.00044690803,0.0008252267,0.00026830652],"domain_scores_gemma":[0.9937918,0.0046169,0.0004328411,0.00047736938,0.00043591656,0.00024516112],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0076674917,0.00014028237,0.0010587139,0.00017096149,0.00013310423,0.000036941223,0.000041484098,0.00008249737,0.000029981837],"category_scores_gemma":[0.013319556,0.000067622794,0.00016250672,0.00047027686,0.0012258254,0.00006126732,0.00007752921,0.00044355667,3.5587865e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92956626,0.0024433,0.029273435,0.00022092175,0.0023177364,0.00054807233,0.0004456147,0.0000019033266,0.000028803624,0.00067086995,0.00041770446,0.034065396],"study_design_scores_gemma":[0.96903265,0.0038233544,0.022087654,0.00031905493,0.0008998064,0.00003376646,0.0007055301,0.00009313401,0.000047209916,0.0011325337,0.0017134016,0.00011190898],"about_ca_topic_score_codex":0.0018167109,"about_ca_topic_score_gemma":0.00034026595,"teacher_disagreement_score":0.039466403,"about_ca_system_score_codex":0.00006374375,"about_ca_system_score_gemma":0.0015233306,"threshold_uncertainty_score":0.99499166},"labels":[],"label_agreement":null},{"id":"W7114793570","doi":"10.1016/j.jtocrr.2025.100943","title":"The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi","keywords":"Immunohistochemistry; Expression (computer science); Stage (stratigraphy); Lung cancer; Mutation; Carcinoma; Gene expression","score_opus":0.07515196479485364,"score_gpt":0.5117377463484276,"score_spread":0.43658578155357397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114793570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95867455,0.003904337,0.0000070076267,0.005112771,0.00004197753,0.0002397993,0.000002027604,0.000009889294,0.032007653],"genre_scores_gemma":[0.9894865,0.0013742686,0.00003393579,0.000058883747,0.000053535798,0.00004896746,0.000008012178,0.0000035985008,0.008932262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853593,0.00007279317,0.000609379,0.000250564,0.00033912857,0.00019219419],"domain_scores_gemma":[0.9982822,0.0009799277,0.00006385754,0.00037966153,0.00016509803,0.00012928947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002738455,0.00005773068,0.00019551633,0.00002388225,0.00012855958,0.000012557398,0.00007953493,0.00013874918,0.000032498207],"category_scores_gemma":[0.002244033,0.000034081168,0.00006342745,0.00024507035,0.00060960546,0.00001478217,0.00010604812,0.0007056678,0.0000010509032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049579726,0.0005855884,0.11621672,0.00026284123,0.000033257158,0.00012657052,0.000019183726,2.1673591e-7,0.7678031,0.00012985765,0.09710099,0.017225925],"study_design_scores_gemma":[0.002093596,0.00017384092,0.06386786,0.000825724,0.000037937563,0.000119384145,0.00032393195,0.00016605327,0.65493864,0.004079496,0.27322704,0.00014652072],"about_ca_topic_score_codex":0.0000105287245,"about_ca_topic_score_gemma":2.4157345e-7,"teacher_disagreement_score":0.17612605,"about_ca_system_score_codex":0.000016262007,"about_ca_system_score_gemma":0.00018294954,"threshold_uncertainty_score":0.30658147},"labels":[],"label_agreement":null},{"id":"W7114800430","doi":"10.1016/j.jtocrr.2025.100944","title":"Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies","year":2025,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC","funders":"International Association for the Study of Lung Cancer","keywords":"Targeted therapy; Lung; Cell; Cell therapy; Acquired resistance; Immunotherapy","score_opus":0.07505819556033028,"score_gpt":0.5350332632889704,"score_spread":0.4599750677286401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114800430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97014254,0.009904338,0.000017197735,0.00909277,0.000102609316,0.00057172717,0.0000020170664,0.000015365375,0.010151439],"genre_scores_gemma":[0.9898711,0.004076525,0.0004564276,0.0004271684,0.00005651595,0.00006368293,0.0000029019495,0.0000056638582,0.0050400193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864966,0.00009985018,0.00039852405,0.00038664538,0.00024886584,0.00021646055],"domain_scores_gemma":[0.9991355,0.0002897535,0.00003624153,0.00017554751,0.00019343532,0.0001695429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001193198,0.000079121724,0.0002596237,0.00011584494,0.00012471496,0.00005760574,0.000021526592,0.00007067468,0.000014061381],"category_scores_gemma":[0.00052685494,0.00005499003,0.000023266553,0.00028628382,0.0002948637,0.000071469454,0.000050278315,0.00025468247,4.9477825e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008944595,0.00028970267,0.89364624,0.00019318603,0.00013210493,0.0013353463,0.0013757262,0.0000023116693,0.0007650233,0.002414049,0.006671623,0.09228021],"study_design_scores_gemma":[0.0016917808,0.00034507754,0.93850404,0.0004580415,0.000013597071,0.000018738572,0.0009628786,0.000018707358,0.000117071446,0.00560541,0.052189127,0.000075516626],"about_ca_topic_score_codex":0.00020654526,"about_ca_topic_score_gemma":0.0003751043,"teacher_disagreement_score":0.09220469,"about_ca_system_score_codex":0.000025509327,"about_ca_system_score_gemma":0.000355413,"threshold_uncertainty_score":0.22424284},"labels":[],"label_agreement":null}]}